



Anticoagulation Desktop Reference

(Version 3.1)

A Consortium-Developed Compendium of Anticoagulation Information

This reference was produced by the **Michigan Anticoagulation Quality Improvement Initiative (MAQI²)**, a consortium of anticoagulation [clinics and experts](#) from across the state of Michigan. Funding for MAQI² is provided by **Blue Cross Blue Shield of Michigan and Blue Care Network** through the [Collaborative Quality Improvement](#) (CQI) program.

The goal of this reference is to provide practitioners with an up-to-date, reliable, and easy to use source of information for anticoagulation. The content is based on the latest available evidence-based guidelines and research, whenever possible. If you are aware of new guidelines or research, or if you have suggestions that can help improve this reference, please [email](#).

What's new in version 3.1?

- Updated choice of anticoagulant information in patients with atrial fibrillation or venous thromboembolism based on the 2026 ACC Scientific Statement on Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events (pages 17-20)
- Added a flowchart for determining the need for extended low-dose apixaban treatment in patients completing 3 months of full-dose anticoagulation for provoked venous thromboembolism based on the HI-PRO trial. (page 28)

Disclaimer: This document is for informational purposes only and does not, itself, constitute medical advice. The information included is not a replacement for careful medical judgments by qualified medical personnel. There may be information in this document that does not apply to or may be inappropriate for the medical situation at hand.

Table of Contents

(push Ctrl+F to search entire document for a keyword)

Determining need and evaluating risk Atrial fibrillation (AF) • Stroke risk evaluation in A-fib patients (p. 1) • Bleeding risk evaluation (p. 2) Venous Thromboembolism (VTE) • Bleeding risk evaluation (p. 3) Other risk evaluation models • Bleeding risk models (p. 4) • Online calculators and apps (p.4)	Anticoagulant selection • Warfarin information (p.5) • DOAC information (p.6) • Nonvalvular atrial fibrillation definitions (p. 14) • Comparison of anticoagulants (p. 15) • Anticoagulant selection based on patient factors (p. 17) • Identifying patients appropriate for DOACs (p. 21) • Pros and cons of DOACs (p. 22)
Warfarin Initiation • Things to consider before starting pt on warfarin (p. 23) • Target INR and length of treatment (p. 24) • Starting dose (p. 29) • Initial dosing nomograms (p. 31) • Initial VTE treatment setting (p. 33) • Converting from DOAC to warfarin (p. 34) • Drug-Drug interactions (p. 35) Patient education • Education topic checklist (p. 36) • Education materials (p. 37) Long-term management • Maint. dosing and recall nomogram (p. 38) • Periprocedural management (p. 40) • Elective Cardioversion (p. 45) • Managing interactive drugs (p. 46) • Routine follow-up questions (p. 48) • Patient self-management (p. 49) • Minor bleeding on anticoagulants (p. 50) • Epistaxis management protocol (p. 51) • Warfarin reversal (p.52) • Restarting anticoagulation after bleed (p. 54)	DOACs Initiation • Dosing by indication (p.6) • DOAC initiation checklist (p.56) • ICHECK'D Mnemonic for DOAC initiation (p. 57) • Converting from other anticoagulants (p. 63) • Length of Treatment for VTE (p. 26) • Initial VTE treatment setting (p. 31) • Drug-Drug/Supplement interactions (p. 58) Patient education • Education topic checklist (p. 64) • Education materials (p. 65) Long-term management • Routine follow-up checklist (p. 66) • DOAC Management Plan Flowchart (p. 67) • Periprocedural management (p. 68) • Measurement and reversal (p. 72) • Bleeding management (p. 73) • Converting to other anticoagulants (p. 78) • DOAC Patient Cards (p.79) • Minor bleeding on anticoagulants (p. 50) • Epistaxis management protocol (p. 51) • Restarting anticoagulation after bleed (p. 54)
Special Populations/Situations • AF in pregnancy (p. 86) • VTE in pregnancy (p. 88) • Unique VTE situations (p.91) • Anticoagulant-Antiplatelet combo tx (p. 94) • VTE prophylaxis in ambulatory CA (p. 97) • VTE treatment/prophylaxis in COVID-19 (p. 99) • Antiplatelet periprocedural management (p. 100) • Anticoagulation in cirrhosis (p.101)	
Other Information • Quality Improvement tools (p. 80) • Anticoagulation Links (p. 102)	

Bleeding/Clotting Risk Evaluation Tools for Atrial Fibrillation Patients

Before prescribing anticoagulants, providers should weigh the risk of thrombosis against the risk of bleeding. The tools below can be used to help providers and patients make informed decisions about whether anticoagulation is warranted.

Stroke Risk Scores

CHA₂DS₂-VASc

The CHA₂DS₂-VASc score is an expansion of the original CHADS₂ score to include 3 additional stroke risk factors: age 65-74, female sex, and history of vascular disease. The additional risk factors are believed to more accurately determine stroke risk and the need for anticoagulation in patients with CHADS₂ scores of 0 or 1. **The CHA₂DS₂-VASc is recommended over CHADS₂ since the 2014 AHA/ACC/HRS Atrial Fibrillation Guidelines.**

CHA ₂ DS ₂ -VASc Scoring Tool ²	
Condition	Points
Congestive heart failure	1
Hypertension	1
Age ≥ 75 years	2
Diabetes mellitus	1
Stroke/TIA or thromboembolism (prior)	2
Vascular disease (MI, PAD, or aortic plaque)	1
Age 65-74 years	1
Sex Category (Female)	1
Total score=	

Score	Risk	ACC/AHA/ACCP Guidelines ¹
≥3	High	Anticoagulate (men and women)
2	High (men) Intermediate (women)	Anticoagulate (men) Reasonable to anticoagulate (women)*
1	Intermediate (men) Low (women)	Reasonable to anticoagulate (men)* Omit anticoagulation (women)
0	Low	Omit anticoagulation

*Consider other stroke risk factors, such as AF burden and degree of hypertension control in patients with intermediate stroke risk.

Aspirin alone or in combination with another antiplatelet is not recommended for stroke prevention.¹

CHA ₂ DS ₂ -VASc Score	Yearly Stroke Risk (%)		
	No Warfarin	With Aspirin ³	With Warfarin ³
0	0	0	0
1	1.3	1.0	0.5
2	2.2	1.8	0.8
3	3.2	2.6	1.1
4	4.0	3.2	1.4
5	6.7	5.4	2.3
6	9.8	7.8	3.4

The 2024 ESC Atrial Fibrillation guidelines recommend omitting the sex category. The guidelines recommend anticoagulation in patients with a CHA₂DS₂-VA score of ≥2 and to consider anticoagulation if score is 1.⁴

¹Joglar, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation Circulation. 2023;148:e00–e00. DOI: 10.1161/CIR.0000000000001193

²Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb;137(2):263-72. doi: 10.1378/chest.09-1584.

³Robert G. Hart, MD; Lesly A. Pearce, MS; and Maria I. Aguilar, MD. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation. Ann Intern Med. 2007;146:857-8673. doi:10.7326/0003-4819-146-12-200706190-00007

⁴2024 ESC Guidelines for the management of atrial fibrillation . European Heart Journal, Volume 45, Issue 36, 21 September 2024, Pages 3314–3414, <https://doi.org/10.1093/eurheartj/ehae176>

Bleeding Risk Scores

Bleeding risk should be assessed at each patient contact and should initially focus on potentially modifiable risk factors. The HAS-BLED tool can be used to identify modifiable risk factors (in red). Patients with scores indicating high bleed risk (≥ 3) should be followed more closely.¹ **In patients at high stroke risk, bleeding risk should not be used in isolation to determine eligibility for oral anticoagulation but instead used to identify/modify bleeding risk factors and to inform medical decision-making.**²

HAS-BLED Score (warfarin in atrial fibrillation patients)³

Estimates risk of major bleeding for patients on **warfarin** for **atrial fibrillation**.

	Condition	Points
H	Hypertension	1
A	Abnormal renal/liver function (1 pt each)	1 or 2
S	Stroke	1
B	Bleeding history or disposition	1
L	Labile INRs	1
E	Elderly	1
D	Current drugs (medication) or alcohol use (1pt each)	1 or 2
TOTAL POINTS		

Total Points	Annual Major bleed risk (%)	Intracranial bleeds per 100-pt-yrs ⁴	Major bleed risk category
0	1.13		Low
1	1.02		Low
2	1.88	0.6	Intermediate
3	3.74	0.7	High
4	8.7	1.0	High
5	12.5	1.2	High

Modifiable risk factors in **red**.

Condition	Definition
Hypertension	Systolic Blood Pressure >160
Abnormal renal function	Chronic dialysis, renal transplantation, serum creatinine ≥ 2.26 mg/dl, or CrCl <50
Abnormal liver function	Chronic hepatic disease/biochemical evidence of hepatic derangement (eg, bilirubin $>2\times$ upper limit of normal, with AST/ALT/Alk Phos $>3\times$ upper limit normal)
Stroke	Any previous history of Stroke
Bleeding history or disposition	Bleeding event history (defined below), genetic predisposition, anemia.
Labile INRs	$<60\%$ of time spent in therapeutic INR range (INR 2-3)
Elderly	Age ≥ 65 years
Current medication or alcohol use	Concomitant use of antiplatelet agent/aspirin, NSAIDs, or alcohol >16 beers/week, >10 glasses wine/week or equivalent

Bleeding event	Bleeding requiring hospitalization and/or causing a decrease in Hgb>2g/dL and/or requiring ≥2 unit blood transfusion.
----------------	---

¹Lipp G, et al. Antithrombotic Therapy for Atrial Fibrillation CHEST Guideline and Expert Panel Report. CHEST 2018; 154(5):1121-1201

²Joglar, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation Circulation. 2023;148:e00–e00. DOI: 10.1161/CIR.0000000000001193

³Pisters R, Lane DA, Nieuwlaet R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010 Nov;138(5):1093-100. doi: 10.1378/chest

⁴Friberg L, Rosenqvist M, Lip G. Net Clinical Benefit in Patients With Atrial Fibrillation: A Report From the Swedish Atrial Fibrillation Cohort Study. Circulation. 2012; 125: 2298-2307. Doi: 10.1161/CIRCULATIONAHA.111.055079

DOAC Score (DOACs in AF)

Estimates bleeding risk in patients on **DOACs** for **atrial fibrillation**.

Condition	Points
Age 65–69	2
Age 70–74	3
Age 75–79	4
Age ≥80	5
Creatinine clearance 30-60 mL/min*	1
Creatinine clearance <30 mL/min*	2
Underweight (BMI <18.5 kg/m ²)	1
Stroke/transient ischemic attack/embolism history	1
Diabetes	1
Hypertension	1
Aspirin use	2
Dual-antiplatelet	3
NSAID use	1
Bleeding history (minor or major)	3
Liver disease**	2
TOTAL POINTS	

Total points	Bleed risk category
0-3	Very low
4-5	Low
6-7	Moderate
8-9	High
≥10	Very high

*Cockcroft-Gault equation

** defined as AST, ALT, ALP ≥3X upper limit of normal, ALP ≥2X upper limit of normal, or cirrhosis

Aggarwal R, et al. Development and Validation of the DOAC Score: A Novel Bleeding Risk Prediction Tool for Patients With Atrial Fibrillation on Direct-Acting Oral Anticoagulants. Circulation. 2023 Sep 19;148(12):936-946. doi: 10.1161/CIRCULATIONAHA.123.064556. Epub 2023 Aug 25. PMID: 37621213; PMCID: PMC10529708.

RIETE Predictive Score for bleeding (warfarin in acute venous thromboembolism)

Estimates risk of major bleeding for patients on **warfarin** for **acute venous thromboembolism**.

Condition	Points
Recent major bleeding (<15 days prior to VTE)	2
Creatinine >1.2 mg/dl	1.5
Anemia (Hgb <13 g/dl in men or <12 g/dl in women)	1.5
Cancer	1
Clinically overt Pulmonary Embolism	1
Age >75 years	1
TOTAL POINTS	

Total Points	Major bleeding (%)	Risk level
0	0.1	Low
1	1.4	Moderate
1.5-2	2.2	
2.5-3	4.4	
3.5-4	4.2	
4.5-5	4.9	High
5.5-6	11	
>6	20	

Ruiz-Giménez et al. Thromb Haemost. 2008 Jul;100(1):26-31. doi: 10.1160/TH08-03-0193

Other Bleeding Risk Models

General bleeding Risk

- IMPROVE: Factors at Admission Associated With Bleeding Risk in Medical Patients. Chest. 2011;139(1):69-79.

VTE treatment

- Outpatient Bleeding Risk Index: The outpatient bleeding risk index: validation of a tool for predicting bleeding rates in patients treated for deep venous thrombosis and pulmonary embolism. Arch Intern Med. 2003 Apr 28;163(8):917-20.
- Kuijer: Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999; 159: 457–60.
- Kearon: Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003 Aug 14;349(7):631-9.

AF treatment

- ATRIA: A New Risk Scheme to Predict Warfarin-Associated Hemorrhage. The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. J Am Coll Cardiol. 2011;58(4):395-401.
- HEMORR₂HAGES: Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006;151:713–9.

Online risk calculators and apps

<http://www.mdcalc.com/chads2-score-for-atrial-fibrillation-stroke-risk/>

<http://www.mdcalc.com/cha2ds2-vasc-score-for-atrial-fibrillation-stroke-risk/>

<http://www.sparctool.com/>

<https://itunes.apple.com/us/app/anticoagevaluator/id609795286?mt=8>

Warfarin Information

Generic (Trade Name)	FDA approved indications	Warnings and Additional Info
Warfarin (Coumadin®, Jantoven®) ¹	- Prophylaxis and treatment of venous thromboembolism (VTE)* - Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation* and/or cardiac valve replacement - Reduction in the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction <i>*DOACs now recommended over warfarin in patients with DVT of the leg or PE and atrial fibrillation (except in patients with moderate-to-severe mitral stenosis or a mechanical heart valve)</i>	Dosage customized so that INR is in therapeutic range. See INR target range table for recommended INR target ranges. Available pill strengths: 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg, 10 mg In patients on warfarin with consistently low time in INR therapeutic range (eg, TTR < 65%), CHEST guidelines recommend considering interventions to improve TTR or switching to a DOAC. Possible interventions include: more regular INR tests, review medication adherence, address other factors known to influence INR control, education/counselling²

¹ Coumadin® [package insert](#)

² Lipp G, et al. Antithrombotic Therapy for Atrial Fibrillation CHEST Guideline and Expert Panel Report. CHEST 2018; 154(5):1121-1201

DOAC Information (from package inserts)

Nonevidence-based doses of DOACs should be avoided to reduce risk of thromboembolic or bleeding adverse events (2023 ACC/AHA/ACCP AF guidelines⁵). Contact us at info@magi2.org if you would like information on our DOAC Dashboard, a population-based EMR tool to identify off-label DOAC prescribing within your organization.

DOAC Standard Dosing Summary Table (see table below for more information)

	Apixaban (Eliquis®) ¹	Dabigatran (Pradaxa®) ²	Edoxaban (Savaysa®) ³	Rivaroxaban (Xarelto®) ⁴
Atrial Fibrillation (non-valvular)	• 5 mg BID • 2.5 mg BID (if at least 2 of the following are met: ≥80yr, ≤60kg, SCr ≥1.5 mg/dl [or on dialysis])	• 150 mg BID • 75 mg BID (if CrCl 15-30 mL/min)	• 60 mg QD (if CrCl 51-95) • 30 mg QD (if CrCl 15-50 mL/min) • Avoid if CrCl >95 mL/min	• 20 mg QD • 15 mg QD (if CrCl ≤50 mL/min)
VTE treatment	• 10 mg BID (first 7 days) • 5 mg BID (after 7 days)	• 150 mg BID (after 5-10 days of parenteral anticoagulant)	• 60 mg QD (after 5-10 days of parenteral anticoagulant) • 30 mg QD (if CrCl 15-50 mL/min or body weight ≤60 kg)	• 15 mg BID (first 21 days) • 20 mg QD (after 21 days)
VTE secondary prevention	• 2.5 mg BID (after at least 6 months of treatment)	• 150 mg BID	N/A	• 10 mg QD (after at least 6 months of treatment)
VTE prophylaxis (knee and hip replacement)	• 2.5 mg BID (12 days for knee, 35 days for hip)	For hip only: • 110 mg (day 1) • 220 mg QD (for 28-35 days)	N/A	• 10 mg QD (12 days for knee, 35 days for hip)
CV event prevention in CAD	N/A	N/A	N/A	• 2.5 mg BID in combination with daily ASA (at least 75-100 mg)
Thrombotic Vascular event reduction in PAD	N/A	N/A	N/A	• 2.5 mg BID in combination with daily ASA (at least 75-100 mg)
VTE prophylaxis in adult patients hospitalized for acute illness	N/A	N/A	N/A	• 10 mg daily (for 31-39 days)

Detailed DOAC information from package inserts

	Apixaban (Eliquis®) ¹	Dabigatran (Pradaxa®) ²	Edoxaban (Savaysa®) ³	Rivaroxaban (Xarelto®) ⁴
General information for all indications	- Not recommended in patients with severe hepatic impairment (Child-Pugh C) - Not recommended in patients with mechanical heart valves or moderate to severe mitral stenosis - Avoid use in pregnant women. Available data about use in pregnant women are insufficient to determine whether there are drug-associated risks for adverse developmental outcomes - Not recommended as first-line therapy in patients with antiphospholipid antibody syndrome (APS) - Avoid concomitant use with donanemab or lecanemab due to increased risk of bleeding - Avoid concomitant use with strong dual inducers of CYP3A4 and P-gp (examples): apalutamide, carbamazepine, fosphenytoin, phenytoin, rifampin, St. John's wort - If receiving 5 mg or 10 mg BID, dose should be reduced by 50% when given with strong dual inhibitors of CYP3A4 and P-gp* - If receiving 2.5 mg BID, avoid concomitant use with strong	- Not recommended in patients with mechanical heart valves or moderate to severe mitral stenosis - Avoid use in pregnant women. Available data about use in pregnant women are insufficient to determine whether there are drug-associated risks for adverse developmental outcomes - Not recommended as first-line therapy in patients with antiphospholipid antibody syndrome (APS) - Avoid concomitant use with donanemab or lecanemab due to increased risk of bleeding - Concomitant use with P-gp inducers should generally be avoided (examples): apalutamide, carbamazepine, fosphenytoin, phenytoin, rifampin, St. John's wort - Consider alternative anticoagulation in patients who develop significant acute renal failure	- Not recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C) - Not recommended in patients with mechanical heart valves or moderate to severe mitral stenosis - Avoid use in pregnant women. Available data about use in pregnant women are insufficient to determine whether there are drug-associated risks for adverse developmental outcomes - Not recommended as first-line therapy in patients with antiphospholipid antibody syndrome (APS) - Avoid concomitant use with donanemab or lecanemab due to increased risk of bleeding - Avoid concomitant use with P-gp inducers (examples): apalutamide, carbamazepine, fosphenytoin, phenytoin, rifampin, St. John's wort	- Not recommended in patients with moderate or severe hepatic impairment (Child-Pugh B or C) or associated coagulopathy - Not recommended in patients with mechanical heart valves or moderate to severe mitral stenosis - Avoid use in pregnant women. Available data about use in pregnant women are insufficient to determine whether there are drug-associated risks for adverse developmental outcome - Not recommended as first-line therapy in patients with antiphospholipid antibody syndrome (APS) - Avoid concomitant use with donanemab or lecanemab due to increased risk of bleeding - Not recommended in patients with transcatheter aortic valve replacement (TAVR), if TAVR is lone indication for anticoagulation - Avoid concomitant use with drugs that are combined P-gp and strong CYP3A4 inducers (examples): apalutamide, carbamazepine, fosphenytoin, phenytoin, rifampin, St. John's wort

	Apixaban (Eliquis®) ¹	Dabigatran (Pradaxa®) ²	Edoxaban (Savaysa®) ³	Rivaroxaban (Xarelto®) ⁴
	dual inhibitors of CYP3A4 and P-gp* *Strong dual inhibitors of CYP3A4 and P-gp (examples): (#= systemic) itraconazole[#], ketoconazole[#], ritonavir, cobicistat, posaconazole, tucatinib NOTE: Although clarithromycin is a combined P-gp and strong CYP3A4 inhibitor, pharmacokinetic data suggest that no dose adjustment is necessary with concomitant administration. There is limited data assessing the clinical significance of a possible interaction with strong CYP3A4 Inducers (enzalutamide, lumacaftor, mitotane, phenobarbital, primidone), consider patients thrombotic risk			- Avoid concomitant use with combined P-gp and strong CYP3A4 inhibitors (examples): (#= systemic) itraconazole[#], ketoconazole[#], ritonavir, cobicistat, posaconazole, tucatinib NOTE: Although clarithromycin is a combined P-gp and strong CYP3A4 inhibitor, pharmacokinetic data suggest that no dose adjustment is necessary with concomitant administration. - Avoid with CrCl < 80 mL/min and receiving concomitant combined P-gp and moderate CYP3A4 inhibitors (examples): (#= systemic) dronedarone, erythromycin[#], verapamil - Clinical implications of this drug combination are somewhat uncertain, refer to Pham P, et al publication in footnotes. - There is limited data assessing the clinical significance of a possible interaction with strong CYP3A4 Inducers (enzalutamide, lumacaftor, mitotane, phenobarbital, primidone), consider patients thrombotic risk

	Apixaban (Eliquis®) ¹	Dabigatran (Pradaxa®) ²	Edoxaban (Savaysa®) ³	Rivaroxaban (Xarelto®) ⁴
Non-valvular Afib	Standard Dose= 5 mg BID If at least 2 of the following characteristics are present: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL (or on dialysis), switch to recommended dose of 2.5 mg BID	Standard Dose= 150 mg BID - Avoid if CrCl <15 mL/min or on dialysis - Reduce dose to 75 mg BID if CrCl 15-30 mL/min - Reduce dose to 75 mg BID if CrCl >30-50 mL/min with concomitant use of CERTAIN P-gp inhibitors dronedarone or systemic ketoconazole NOTE: No dose adjustment necessary for other P-gp inhibitors such as amiodarone, verapamil, quinidine, or clarithromycin. - CrCl ≤30 mL/min with concomitant use of P-gp inhibitors*: Avoid co-administration * P-gp inhibitors (examples): (#= systemic) amiodarone, azithromycin#, carvedilol, clarithromycin, cobicistat, cyclosporine#, daclatasvir, dronedarone, elagolix, eliglustat, erythromycin#, flibanserin, fostamatinib, glecaprevir/pibrentasvir, itraconazole#, ivacaftor, ketoconazole# lapatinib, ledipasvir, neratinib, osimertinib, posaconazole, propafenone, quinine, quinidine, ranolazine, ritonavir, rolapitant, simeprevir, tucatinib, velpatasvir, vemurafenib, verapamil	Standard Dose= 60 mg QD - Avoid if CrCl >95 mL/min - Reduce dose to 30 mg QD if CrCl is 15-50 mL/min	Standard Dose= 20 mg QD 15 mg QD if ESRD on dialysis - Reduce dose to 15 mg QD if CrCl ≤ 50 mL/min - Consider alternative anticoagulation in patients who develop significant acute renal failure

	Apixaban (Eliquis®) ¹	Dabigatran (Pradaxa®) ²	Edoxaban (Savaysa®) ³	Rivaroxaban (Xarelto®) ⁴
VTE treatment	Standard Dose= 10 mg BID x 7 days, then 5mg BID thereafter	Standard Dose= 150 mg BID after 5-10 days of parenteral bridge - Avoid if CrCl $\leq$30 mL/min or on dialysis - CrCl <50 mL/min with concomitant use of P-gp inhibitors*: Avoid co-administration * P-gp inhibitors (examples): (#= systemic) amiodarone, azithromycin#, carvedilol, clarithromycin, cobicistat, cyclosporine#, daclatasvir, dronedarone, elagolix, eliglustat, erythromycin#, flibanserin, fostamatinib, glecaprevir/pibrentasvir, itraconazole#, ivacaftor, ketoconazole# lapatinib, ledipasvir, neratinib, osimertinib, posaconazole, propafenone, quinine, quinidine, ranolazine, ritonavir, rolapitant, simeprevir, tucatinib, velpatasvir, vemurafenib, verapamil	Standard Dose= 60 mg QD after 5-10 days of parenteral bridge Reduce dose to 30 mg QD if CrCl is 15-50 mL/min or body weight $\leq$60 kg or using certain P-gp inhibitors (examples): (#= systemic) verapamil, quinidine, azithromycin#, clarithromycin#, dronedarone, erythromycin#, itraconazole#, ketoconazole#, cobicistat, tucatinib Use of other p-gp inhibitors with edoxaban has not been studied, but a similar dose reduction approach is likely reasonable.	Standard Dose= 15 mg BID x 21 days, then 20mg daily thereafter - Avoid if CrCl <15 mL/min or if on dialysis - Consider alternative anticoagulation in patients who develop significant acute renal failure
Secondary risk reduction of VTE following initial therapy	After at least 6 months of treatment may switch to 2.5 mg BID	- Avoid if CrCl $\leq$30 mL/min or on dialysis 150 mg BID after previous treatment - CrCl <50 mL/min with concomitant use of P-gp inhibitors*: Avoid co-administration * P-gp inhibitors (examples): (#= systemic) amiodarone, azithromycin#,	Not FDA approved for this indication	- Avoid if CrCl <15 mL/min or if on dialysis - After at least 6 months of standard anticoagulant treatment may switch to 10 mg QD - Consider alternative anticoagulation in patients who develop significant acute renal failure

	Apixaban (Eliquis®) ¹	Dabigatran (Pradaxa®) ²	Edoxaban (Savaysa®) ³	Rivaroxaban (Xarelto®) ⁴
		carvedilol, clarithromycin, cobicistat, cyclosporine [#] , daclatasvir, dronedarone, elagolix, eliglustat, erythromycin [#] , flibanserin, fostamatinib, glecaprevir/pibrentasvir, itraconazole [#] , ivacaftor, ketoconazole [#] lapatinib, ledipasvir, neratinib, osimertinib, posaconazole, propafenone, quinine, quinidine, ranolazine, ritonavir, rolapitant, simeprevir, tucatinib, velpatasvir, vemurafenib, verapamil		
VTE Prophylaxis after hip/knee replacement	Standard Dose= 2.5 mg BID (first dose 12-24 hrs after surgery) for 12 days (knee) or 35 days (hip)	Standard Dose= 110 mg day 1 then 220 mg QD for 28-35 days • Not FDA approved for knee replacement • Avoid if CrCl ≤30 mL/min or on dialysis • CrCl <50 mL/min with concomitant use of P-gp inhibitors*: Avoid co-administration * P-gp inhibitors (examples): (#= systemic) amiodarone, azithromycin [#] , carvedilol, clarithromycin, cobicistat,	Not FDA approved for this indication	Standard Dose= 10 mg QD for 12 days (knee) or 35 days (hip) • Avoid if CrCl <15 mL/min or if on dialysis • Consider alternative anticoagulation in patients who develop significant acute renal failure

	Apixaban (Eliquis®) ¹	Dabigatran (Pradaxa®) ²	Edoxaban (Savaysa®) ³	Rivaroxaban (Xarelto®) ⁴
		cyclosporine [#] , daclatasvir, dronedarone, elagolix, eliglustat, erythromycin [#] , flibanserin, fostamatinib, glecaprevir/pibrentasvir, itraconazole [#] , ivacaftor, ketoconazole [#] lapatinib, ledipasvir, neratinib, osimertinib, posaconazole, propafenone, quinine, quinidine, ranolazine, ritonavir, rolapitant, simeprevir, tucatinib, velpatasvir, vemurafenib, verapamil		
CV event reduction in CAD	Not FDA approved for this indication	Not FDA approved for this indication	Not FDA approved for this indication	Standard Dose= 2.5 mg BID in combination with daily ASA (at least 75-100 mg)
Thrombotic Vascular event reduction in PAD (including lower extremity revasculariza ion)	Not FDA approved for this indication	Not FDA approved for this indication	Not FDA approved for this indication	Standard Dose= 2.5 mg BID in combination with daily ASA (at least 75-100 mg) When starting therapy after a successful lower extremity revascularization procedure, initiate once hemostasis has been established.

	Apixaban (Eliquis®) ¹	Dabigatran (Pradaxa®) ²	Edoxaban (Savaysa®) ³	Rivaroxaban (Xarelto®) ⁴
VTE prophylaxis in adult patients hospitalized for acute illness	Not FDA approved for this indication	Not FDA approved for this indication	Not FDA approved for this indication	In patients who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE and NOT at high risk of bleeding (Patients with bronchiectasis/pulmonary cavitation, active cancer, dual antiplatelet therapy or active gastroduodenal ulcer or any bleeding in the previous three months) Standard Dose= 10 mg daily for 31-39 days. • Avoid if CrCl <15 mL/min or if on dialysis • Consider alternative anticoagulation in patients who develop significant acute renal failure

¹Eliquis® [package insert](#) ²Pradaxa® [package insert](#) ³Savaysa® [package insert](#) ⁴Xarelto® [package insert](#)

⁵Joglar, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation Circulation. 2023;148:e00–e00. DOI: 10.1161/CIR.0000000000001193

- CrCl should be based on the Cockcroft-Gault formula and actual body weight: https://www.kidney.org/professionals/KDOQI/gfr_calculatorCoc
- Unless otherwise noted, recommendations come from package inserts or the AC Forum Direct Oral Anticoagulant (DOAC) Drug-Drug Interaction Guidance (in the Drug Info section of Rapid Resources within the Centers of Excellence): <https://acforum-excellence.org/Resource-Center/?t=rr&g=0#resultsplacemain>
- Pham P, Schmidt S, Lesko L, Lip GYH, Brown JD. Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function. JAMA Netw Open. 2020;3(4):e203593. doi:10.1001/jamanetworkopen.2020.3593
- See [ICHECK'd](#) mnemonic to help with DOAC prescribing

Valvular Atrial Fibrillation Definitions

- Direct Oral Anticoagulants (DOACs) are FDA approved for stroke prevention in patients with “non-valvular” AF; however, there is some confusion around the definition of “valvular” AF.
- The 2023 ACC/AHA/ACCP Atrial Fibrillation guidelines recommend not using the terms “valvular” or “non valvular” when describing AF. Instead, the guidelines differentiate AF patients into those with moderate-to-severe rheumatic mitral stenosis or a mechanical heart valve (in which warfarin is recommended) and those without these conditions (in which DOACs are recommended)¹
- The 2020 ESC guidelines for diagnosis and management of AF recommend not differentiating between valvular and non-valvular AF due to the potential confusion in definitions; however, their guidelines do not recommend DOACs in patients with prosthetic mechanical valves or moderate-to-severe mitral stenosis.²

1. Joglar, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation Circulation. 2023;148:e00–e00. DOI: 10.1161/CIR.0000000000001193
2. Hendricks G, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, Volume 42, Issue 5, 1 February 2021, Pages 373–498, <https://doi.org/10.1093/eurheartj/ehaa612>

Comparison of Anticoagulants

Basic Characteristics of Warfarin and DOACs

	Warfarin	DOACs
Onset	Slow	Rapid
Dosing	Variable	Fixed
Food effect	Yes	Rivaroxaban should be taken with largest meal of the day, otherwise no known food effects for DOACs
Medication interactions	Many	Few*
Therapeutic monitoring required	Yes	No
Offset	Long	Shorter

*Apixaban is contraindicated if patient has two or more of these factors (age≥80, weight ≤60kg, serum creatinine ≥1.5 mg/dL) AND is taking a strong dual CYP3A4 and P-gp inhibitor.

Safety, Efficacy, and Pharmacology

	Warfarin ^a	Rivaroxaban ^a	Apixaban ^a	Dabigatran ^a	Edoxaban ^b
FDA approved indications	• AF • VTE ○ treatment ○ secondary prevention ○ prophylaxis • Valve replacement • MI	• AF (without moderate-to-severe rheumatic mitral stenosis or a mechanical heart valve) • VTE ○ treatment ○ secondary prevention ○ prophylaxis¹ • CV event reduction in stable CAD or PAD • VTE prophylaxis in acutely ill medical patients	• AF (without moderate-to-severe rheumatic mitral stenosis or a mechanical heart valve) • VTE ○ treatment ○ secondary prevention ○ prophylaxis¹	• AF (without moderate-to-severe rheumatic mitral stenosis or a mechanical heart valve) • VTE ○ Treatment³ ○ secondary prevention ○ prophylaxis²	• AF (without moderate-to-severe rheumatic mitral stenosis or a mechanical heart valve) • VTE ○ Treatment³
Administration	• Once daily with or without food	• Once or twice daily with largest meal of day⁴	• Twice daily with or without food	• Twice daily with or without food • Must be kept in original packaging • Can't be crushed	• Once daily with or without food
Safety in non-valvular atrial fibrillation	• Higher risk of intracranial hemorrhage compared to DOACs	• Higher risk of GI bleeding compared to warfarin	• Lower risk of major bleeding compared to warfarin	• Higher risk of GI bleeding compared to warfarin • Small increase in risk of MI compared to warfarin	• Lower risk of major bleeding compared to warfarin • Higher risk of GI bleeding (60mg dose) compared to warfarin
Efficacy in non-valvular atrial fibrillation⁵		• Non-inferior to warfarin	• Reduced all-cause mortality	• Lower risk of ischemic stroke (150mg dose only) • Trend towards reduced all-cause mortality	• Non-inferior to warfarin
Safety in VTE	• Increased risk of intracranial hemorrhage^d	• Lower risk of major bleeding than warfarin^c • May have higher risk of GI bleeding than warfarin^d	• Potentially lower risk of major bleeding than warfarin, LMWH/dabigatran,	• May have higher risk of GI bleeding than warfarin^d	• May have higher risk of GI bleeding than warfarin^d

	Warfarin ^a	Rivaroxaban ^a	Apixaban ^a and LMWH/edoxaban ^c	Dabigatran ^a	Edoxaban ^b
Efficacy in VTE	Similar reduction in risk of recurrence ^c	Similar reduction in risk of recurrence ^c	Similar reduction in risk of recurrence ^c	Similar reduction in risk of recurrence ^c	Similar reduction in risk of recurrence ^c
Initial parenteral therapy needed for VTE treatment?	Yes	No	No	Yes	Yes
Drug interactions	Multiple	3A4/P-gp	3A4/P-gp	P-gp	P-gp
Target	VKORC1	Factor Xa	Factor Xa	Thrombin	Factor Xa
Prodrug	No	No	No	Yes	No
Bioavailability	100%	60%-80% ⁶	60%	6%	62%
Time to peak effect	4-5 days	2-4 hours	1-2 hours	1-3 hours	1-2 hours
Half-life	40 hours	7-11 hours	12 hours	8-15 hours	10-14 hours
Renal clearance	None	33%	25%	80%	50%

¹Approved for VTE prophylaxis following knee or hip surgery only.

²Approved for VTE prophylaxis following hip surgery only.

³After 5-10 days of parental anticoagulant treatment only

⁴Twice daily for first 21 days of VTE treatment. Once daily for other indications.

⁵All are considered effective for stroke reduction in non-valvular AF

⁶Bioavailability of rivaroxaban decreases as the dose is increased. With once daily doses of 20 and 10 mg, bioavailabilities are 60% and 80%, respectively

^aAdapted from: Weitz JI, Gross PL. New oral anticoagulants: which one should my patient use? Hematology Am Soc Hematol Educ Program. 2012;2012:536-40. doi: 10.1182/asheducation-2012.1.536.

^bU.S. edoxaban package insert

^cCastellucci LA. JAMA. 2014;312(11):1122-1135

^dKearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy For VTE Disease: Chest Guideline Published online January 07, 2016. doi:10.1016/j.chest.2015.11.026.

For more details on the individual trials comparing warfarin with each of the DOACs/DOACs see:

Rivaroxaban (ROCKET-AF) DOI: 10.1056/NEJMoa1009638

Apixaban (ARISTOTLE) DOI: 10.1056/NEJMoa1107039

Dabigatran (RE-LY) DOI: 10.1056/NEJMoa0905561

Edoxaban (ENGAGE AF) DOI: 10.1056/NEJMoa1310907

Choice of Anticoagulant in AF Based on Patient Characteristics*

Patient Characteristic		Drug Choice	Rationale
Mechanical Heart Valve (valvular AF)		warfarin	Dabigatran inferior to warfarin and contraindicated in this group; other DOACs not studied in this patient population
Moderate-severe rheumatic mitral valve disease		warfarin	The INVICTUS trial found higher rates of cardiovascular events and mortality in patients treated with rivaroxaban vs warfarin. ¹ ACC/AHA guidelines recommend warfarin as first line in these patients ²
Bioprosthetic valves		Warfarin or DOAC (if valve placed >3 months)	DOACs are a reasonable alternative to warfarin in patients with AF and bioprosthetic valves in place for at least 3 months. ³
Chronic Kidney Disease²	Stage 3 (CrCl 30-59 mL/min)	DOAC preferred Warfarin acceptable	Available data suggests that evidenced-based doses of DOACs can safely be used in patients with CKD. Follow package insert instructions for proper dosing.
	Stage 4 (CrCl 15-29 mL/min)	Warfarin or DOAC	
	End-stage (CrCl<15 mL/min) or on dialysis	Warfarin or apixaban	
Hepatic impairment	Mild (Child-Pugh A)	DOACs (standard dosing) ⁸	Based on available evidence suggesting greater efficacy and safety compared to VKAs.
	Moderate (Child-Pugh B)	Apixaban or dabigatran	Rivaroxaban not recommended per 2026 ACC statement due to elevated bleed risk ⁹ Edoxaban not recommended per package insert
	Severe (Child-Pugh C)	Warfarin	There is insufficient evidence to support DOAC use ⁹
Triple Positive Antiphospholipid Syndrome (APS)		warfarin	DOACs are contraindicated in patients with triple positive antiphospholipid syndrome
Stable on warfarin[†]		warfarin or DOAC	Patients on warfarin should be informed about DOACs so they can make an informed decision on preferred anticoagulant
Dyspepsia or upper gastrointestinal symptoms		warfarin, rivaroxaban, apixaban, or edoxaban	Dyspepsia in up to 10% of patients taking dabigatran.
Extremes of weight		Warfarin or DOACs	A large, retrospective study of >36,000 AF patients found that DOACs had better safety and effectiveness compared to warfarin across all BMI categories, including the underweight and morbidly obese. ⁴ ISTH guidelines state that apixaban or rivaroxaban are acceptable oral anticoagulant options in patients with BMI >40 kg/m ² or weight >120 kg, along with warfarin, for VTE ⁵
Bariatric surgery (gastric-bypass, lap band surgery, or gastrectomy)		warfarin	Due to possible altered absorption and lack of data on efficacy, DOACs are not recommended in patients that have had bariatric surgery. ⁶
Recent gastrointestinal bleed		Warfarin or apixaban	More GI bleeds with dabigatran (150mg), rivaroxaban, or edoxaban (60mg) than with warfarin. Warfarin easier to reverse if there is further bleeding.

Prior unprovoked bleeding, warfarin-associated bleeding, or at high risk of bleeding	Apixaban, Edoxaban, dabigatran (110mg BID)	All of these options demonstrate significantly less major bleeding compared with warfarin. ⁷ Apixaban or low-dose dabigatran (110mg BID) preferred ⁹
Requirement for compliance aid such as medication planner/pill box	warfarin, rivaroxaban, apixaban, or edoxaban	Dabigatran capsules must be kept in their original container.
Stroke prevention in AF patients with CrCl > 95 mL/min	warfarin, dabigatran, rivaroxaban, or apixaban	Edoxaban inferior to warfarin in these patients based on post hoc analysis and contraindicated by FDA.
Frailty/elderly at risk for thromboembolism	Apixaban	Apixaban is preferred DOAC due to its lower risk of bleeding ⁹

*Based on MAQI² expert consensus unless otherwise referenced.

[†]Warfarin dose has been stable and INRs have mostly been in therapeutic range.

¹ Connolly SJ, Karthikeyan G, Ntsekhe M, et al., on behalf of the INVICTUS Investigators. Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation. N Engl J Med 2022;387:978-88.

² Joglar, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation Circulation. 2023;148:e00–e00. DOI: 10.1161/CIR.0000000000001193

³ Otto C, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923

⁴ Barakat AF et al. Outcomes of Direct Oral Anticoagulants in Atrial Fibrillation Patients Across Different Body Mass Index Categories, JACC: Clinical Electrophysiology, Volume 7, Issue 5, 2021, Pages 649-658, ISSN 2405-500X, <https://doi.org/10.1016/j.jacep.2021.02.002>.

⁵ Martin KA, et al. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost. 2021;19(8):1874-1882. doi:10.1111/jth.15358

⁶ Am J Med. 2017 May;130(5):517-524. doi: 10.1016/j.amjmed.2016.12.033. Epub 2017 Feb

⁷ Lipp G, et al. Antithrombotic Therapy for Atrial Fibrillation CHEST Guideline and Expert Panel Report. CHEST 2018; 154(5):1121-1201

⁸ Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, Volume 22, Issue 9, 2653 - 2669

⁹ Kumbhani DJ, et al. Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events: 2026 ACC Scientific Statement: A Report of the American College of Cardiology. J Am Coll Cardiol. 2026 Jun 30:S0735-1097(26)06700-8. doi: 10.1016/j.jacc.2026.05.033. Epub ahead of print. PMID: 42377292.

The choice of anticoagulant in AF should be a shared decision; however, American, Canadian, and European guidelines now recommend DOACs over warfarin in patient with AF (except in patients with moderate-to-severe mitral stenosis or a mechanical heart valve).

The Society of Vascular Medicine has developed an online shared decision making tool for providers to use with their patients and families. The tool is available at: <http://www.mybloodclots.org/>

Choice of Anticoagulant in VTE Based on Patient Characteristics

Patient Characteristic		Drug Choice	Remarks
Acute VTE in non-cancer patients		DOACs	Apixaban, dabigatran, edoxaban, or rivaroxaban recommended over VKA during first 3 months. ¹ Apixaban may be preferred over rivaroxaban based on recent comparative evidence from the COBRRA trial and recommendations from the 2026 ACC Scientific Statement on DOACs. ^{6,7}
Acute VTE in patients with cancer (cancer associated thrombus)		apixaban, edoxaban, rivaroxaban, or LMWH	Apixaban, edoxaban, or rivaroxaban recommended over LMWH for initiation and treatment phases (first 3-6 months). (2021 CHEST guidelines and 2021 ASH guidelines) ¹ Apixaban or LMWH may be preferred in patients with luminal GI malignancies and high GI bleed risk. DOACs or LMWH are suggested for long-term anticoagulation (>6 months) (2021 American Society of Hematology guidelines) ² DOACs should be used carefully for patients with GI cancers because of the higher risk of GI bleeding ²
Parenteral therapy to be avoided		Rivaroxaban; apixaban	VKA, dabigatran and edoxaban require initial parenteral therapy.
Once daily oral therapy preferred		Rivaroxaban; edoxaban; warfarin	
Hepatic impairment	Mild (Child-Pugh A)	DOACs, LMWH alone, or warfarin (after LMWH bridging) ⁵	There are limited data evaluating optimal strategies in patients with cirrhosis, as these patients were excluded from most phase III trials. ⁵
	Moderate (Child-Pugh B)	Apixaban, dabigatran, edoxaban, LMWH alone, or warfarin (after LMWH bridging)	Rivaroxaban not recommended per 2026 ACC statement due to elevated bleed risk ⁷ Edoxaban not recommended per package insert
	Severe (Child-Pugh C)	LMWH alone or warfarin (after LMWH bridging in patients with normal baseline INR)	There is insufficient evidence to support DOAC use ⁷
Liver disease and coagulopathy		LMWH	DOACs contraindicated if elevated baseline INR due to liver disease; VKA difficult to control and INR may not reflect antithrombotic effect.
Moderate to severe renal insufficiency		Warfarin or apixaban	Dabigatran is contraindicated if CrCl<30 while edoxaban and rivaroxaban are contraindicated if CrCl <15. There are no contraindications for apixaban use in patients with renal insufficiency. Both apixaban and warfarin are approved for use in patients on hemodialysis.
Coronary artery disease		warfarin, rivaroxaban, apixaban, edoxaban	Coronary artery events appear to occur more often with dabigatran than with VKA. This has not been seen

		with the other DOACs, and they have demonstrated efficacy for coronary artery disease. Antiplatelet therapy should be avoided unless there is a clear indication in patients on anticoagulants because of increased bleeding.
Dyspepsia or history of gastrointestinal bleeding	VKA, apixaban	Dabigatran can cause dyspepsia. Dabigatran, rivaroxaban and edoxaban may be associated with more gastrointestinal bleeding than VKA.
Obesity³	DOACs, warfarin, LMWH, fondaparinux	• BMI up to 40 kg/m² or weight up to 120 kg→any DOAC is appropriate • For VTE treatment regardless of high BMI/weight→ standard dose rivaroxaban or apixaban (warfarin, weight-based LMWH, or fondaparinux are also options. • For VTE primary prevention regardless of high BMI/weight→ rivaroxaban or apixaban
Bariatric surgery³	Parenteral anticoagulants (early postsurgical) VKA or DOAC (>4 wks post surgery)	Parenteral anticoagulants suggested during early postsurgical phase due to concerns of decreased absorption of DOACs. After at least 4 weeks of parenteral treatment, switching to VKA or DOAC can be considered (obtain DOAC trough level to check for drug absorption and bioavailability). See AC Forum rapid resource for more info on DOAC use in bariatric surgery patients: https://acforum-excellence.org/Resource-Center/resource_files/-2021-09-11-103024.pdf
Thrombolytic therapy use	Unfractionated heparin infusion	Greater experience with its use in patients treated with thrombolytic therapy
Pregnancy or pregnancy risk	LMWH	Potential for other agents to cross the placenta
Breast feeding⁴	LMWH or warfarin	It is unknown if DOACs are excreted in breast milk.
Triple Positive Antiphospholipid Syndrome	Warfarin or LMWH	DOACs are contraindicated in patients with triple positive antiphospholipid syndrome
Cost, coverage, licensing	Varies among regions and with individual circumstances	
Frailty/elderly at risk for thromboembolism	Apixaban	Apixaban is preferred DOAC due to its lower risk of bleeding ⁷
History of prior bleeding or elevated bleeding risk	Apixaban	Apixaban preferred based on recent comparative evidence from the COBRRA trial and recommendations from the 2026 ACC Scientific Statement on DOACs. ^{6,7}

¹ Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. CHEST 2021; 160(6):e545-e608

² Lyman, Gary H., et al. "American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer." Blood advances 5.4 (2021): 927-974.

³ Martin KA, et al. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost. 2021;19(8):1874-1882. doi:10.1111/jth.15358

⁴ Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. *Journal of Thrombosis and Thrombolysis*, 2016, Volume 41, Number 1, Page 206

⁵Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH. *Journal of Thrombosis and Haemostasis*, Volume 22, Issue 9, 2653 – 2669

⁶Castellucci LA, et al. Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism. *N Engl J Med*. 2026 Mar 12;394(11):1051-1060. doi: 10.1056/NEJMoa2510703. PMID: 41812192.

⁷Kumbhani DJ, et al. Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events: 2026 ACC Scientific Statement: A Report of the American College of Cardiology. *J Am Coll Cardiol*. 2026 Jun 30;S0735-1097(26)06700-8. doi: 10.1016/j.jacc.2026.05.033. Epub ahead of print. PMID: 42377292.

Identifying Patients Appropriate for Direct Oral Anticoagulants (DOACs)

With the FDA approval of direct oral anticoagulants (DOACs), such as dabigatran (Pradaxa®), rivaroxaban (Xarelto®), apixaban (Eliquis®), and edoxaban (Savaysa®), clinicians have alternatives to warfarin for stroke prevention in non-valvular A-Fib and the prevention/treatment of VTE. Although their safety and efficacy are comparable or better than warfarin and they are easier to manage, DOACs may not be the best choice for all patients. Clinicians must weigh individual patient factors to determine whether a DOAC or warfarin is most appropriate. The criteria and pros and cons below can help providers and patients make an informed decision.

Criteria for Good DOAC Candidates*

Criteria	Rationale
FDA approved indication	DOACs are currently only approved for non-valvular atrial fibrillation and treatment/prevention of VTE. Review prescribing information for DOACs for updated FDA approval information. DOACs are contraindicated in mechanical valve patients.
Adequate renal function	Since DOACs rely on renal function for elimination, they should be used with caution in patients with significant renal disease. DOAC dosing is adjusted according to renal function.
History of compliance with medical regimen	Since DOACs have a short half-life compared to warfarin and do not require monitoring, compliance may be a more important concern.
Frequent medication, diet, or health status changes that make warfarin management difficult.	Unlike warfarin, DOACs have few medication interactions. In addition, the only food-related factor with DOACs is that rivaroxaban should be taken with food.
Barriers to patient/family education	While DOAC education is still important, warfarin education is more involved due to the difficulty of management and number of topics needing to be covered.
Barriers to frequent monitoring (lack of transportation, mobility issues)	Unlike warfarin, frequent blood draws are not necessary with DOACs. Most follow-up monitoring can occur at regularly scheduled medical appointments.
Not taking medications known to interact with DOACs	While DOACs interact with fewer medications, there are still medications that increase or decrease drug exposure depending on the DOAC being used, including P-glycoprotein (Pgp) and strong CYP3A4 inducers and inhibitors (rifampin, ketoconazole, dronedarone, and itraconazole). Prescribing information should be reviewed for complete drug-drug interaction information.

Criteria	Rationale
Financial resources or adequate insurance coverage to pay out-of-pocket expense	DOACs may require higher out-of-pocket expenses based on insurance coverage.
History of labile INRs while on warfarin despite good compliance and efforts to improve INR stability.	In patients unable to maintain therapeutic INR levels, the 2014 AHA/ACC/HRS Atrial Fibrillation Guidelines recommend switching patients to a DOAC (Class IC rec.) ¹
Documented warfarin failure	DOACs should be considered if a patient has a thromboembolic event while on warfarin, especially if the patient's INR was therapeutic at time of event.
Patient understands and accepts that DOACs are not monitored and cannot accurately be measured	Patients need to be part of the decision-making process, which includes informing them about some of the key differences between warfarin and DOACs.

*Based on MAQI² expert consensus unless otherwise noted.

¹ January C, Wann L, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. JACC. 2014. Doi: 10.1016/j.jacc.2014.03.022

Pros and Cons of DOACs*

PROS
Lower incident of intracranial hemorrhage compared to warfarin
Reduced risk of ischemic stroke compared to warfarin in atrial fibrillation (apixaban and dabigatran 150mg)
Lower risk of major bleeding compared to warfarin in AF (apixaban and edoxaban) (rivaroxaban had less major bleeding in pulmonary embolism patients ¹)
Lower overall risk of mortality compared to warfarin (apixaban and dabigatran 150mg)
No INR monitoring required
Bridging/induction therapy likely not needed (except for dabigatran and edoxaban which require 5-10 days of parenteral anticoagulation for treatment of VTE)
Short half-life allows easier perioperative management
Convenient for rural patients or those with other barriers to INR monitoring
Fewer drug/diet/co-morbidity interactions
Less complex patient/family education
Follow up can likely be performed by community providers as well as specialty clinics

CONS
DOACs with BID dosing (dabigatran and apixaban) and rivaroxaban's requirement to take with food may have a negative impact on compliance.
No specific monitoring parameter
Higher incidence of GI side effects and discontinuation rate (dabigatran only)
Possible increased incidence of certain adverse events (e.g. MI, GI bleed, etc.) depending on DOAC
Lack of monitoring may result in non-compliance and an increased chance that patient may not report bleeding
Renal monitoring and dose adjustment required
Higher out-of-pocket costs and copays

*Based on MAQI² expert consensus

¹ EINSTEIN-PE trial: N Engl J Med 2012; 366:1287-1297 April 5, 2012 DOI: 10.1056/NEJMoa1113572

Things to Consider when Starting Warfarin

1. Ensure that patient doesn't have any of these absolute contraindication for warfarin¹

- Pregnancy, except in women with mechanical heart valves
- Hemorrhagic tendencies or blood dyscrasias
- Recent or contemplated surgery of the central nervous system (CNS) or eye, or traumatic surgery resulting in large open surfaces
- Bleeding tendencies associated with certain conditions
- Threatened abortion, eclampsia, and preeclampsia
- Unsupervised patients with potential high levels of non-compliance
- Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding
- Hypersensitivity to warfarin or any component of the product
- Major regional or lumbar block anesthesia
- Malignant hypertension

2. Weigh risk of clotting with risk of bleeding

- In a-fib patients, calculate the patient's stroke risk using [CHADS₂](#) or [CHA₂DS₂-VASc](#) scores and bleeding risk using the [HAS-BLED](#) score.
- In VTE patients, calculate the patient's bleeding risk using the [RIETE bleeding risk score](#).

3. Consider other patient factors that could impact warfarin safety

- Possible drug interactions ([drug interaction table](#))
- Ability of patient/family to comply with monitoring and dose changes and comprehend warfarin education
- Alcohol abuse, dementia, depression, unstable diet, co-morbidities
- Discuss treatment options with cardiologist if patient is also on dual antiplatelet medications

4. Select appropriate target INR range

- [Selecting appropriate target range](#)

5. Select appropriate treatment duration

- [Selecting appropriate duration](#)

6. Select appropriate starting dose

- Select [starting dose](#) based on factors affecting bleeding risk and warfarin sensitivity such as age, co-morbidities, and interacting drugs.

¹ Coumadin® package insert: http://packageinserts.bms.com/pi/pi_coumadin.pdf

Warfarin Target INR Range and Length of Treatment

Table 1. Recommendations for Target INR Range and Duration of Treatment			
Indication	Target INR Range	Duration and additional information	Grade of Recommendation
DVT and PE¹			
PE or DVT of leg <u>provoked</u> by surgery or transient/reversible risk factor	2-3	3 months	1B
PE or DVT of leg <u>unprovoked</u> by surgery or transient/reversible risk factor	2-3	At least 3 months (over shorter period), then evaluate for risk-benefit of extended therapy (see flowchart below) In patients with a first VTE that is an unprovoked proximal DVT of the leg or PE and who have a low or moderate bleeding risk, use extended anticoagulant therapy (no scheduled stop date) over 3 months of therapy (Grade 2B). If high bleeding risk, use 3 months of anticoagulant therapy over extended therapy (no scheduled stop date) (Grade 1B).	1B
PE or DVT of leg in patients with active cancer	2-3	Extended (>3 months) Suggest use of LMWH over warfarin in PE or DVT of leg	1B (2B if high-risk for bleed) 2B
Non valvular atrial fibrillation and/or flutter²			
Low risk (CHA ₂ DS ₂ -VASc =0)	N/A	Reasonable to omit antithrombotic therapy	2A
Intermediate risk (CHA ₂ DS ₂ -VASc =1)	2-3	No antithrombotic therapy or long-term treatment with an oral anticoagulant or aspirin may be considered	2B
High risk (CHA ₂ DS ₂ -VASc ≥ 2)	2-3	Long-term	1A recommendation for warfarin 1B recommendation for dabigatran, rivaroxaban, or apixaban*

Cardioversion	2-3	At least 3 weeks prior to and at least 4 weeks after regardless of CHA ₂ DS ₂ -VASc score or method of cardioversion.	1B
Valvular Disease³			
Mechanical aortic valve replacement (bileaflet or current-generation single tilting disc) and <u>no risk factors for thromboembolism</u>	2-3	Long-term Thromboembolism risk factors: AF, previous thromboembolism, LV dysfunction, or hypercoagulable conditions ASA should be added only if there is a separate indication for antiplatelet therapy (such as recent MI) and there is low risk of bleeding	1B 2B
Mechanical Aortic valve and additional risk factors for thromboembolic events or an older-generation mechanical AVR (such as ball-in-cage)	2.5-3.5 (2-3 may be reasonable, based on provider discretion and prior CHEST guidelines ⁴)	Long-term Thromboembolism risk factors: AF, previous thromboembolism, LV dysfunction, or hypercoagulable conditions ASA should be added only if there is a separate indication for antiplatelet therapy (such as recent MI) and there is low risk of bleeding	1B 2B
Mechanical mitral valve replacement	2.5-3.5	Long-term ASA should be added only if there is a separate indication for antiplatelet therapy (such as recent MI) and there is low risk of bleeding	1B 2B
Bioprosthetic mitral or aortic valve replacement	2.0-3.0	3-6 months (in patients at low risk for bleeding) followed with aspirin	2A
On-X® mechanical <u>aortic</u> valve replacement ³	2.0-3.0 → 1.5-2.0 →	first 3 months (with 75-100mg ASA) after 3 months (with 75-100mg ASA) in patients with no thromboembolic risk factors	2B
Transcatheter aortic valve replacement (TAVR)	2.0-3.0	May be reasonable for at least 3 months, if low risk for bleeding	2B
Post-op VTE prophylaxis^{5***}			
Total hip replacement	2.0-3.0	At least 10 to 14 days Suggestion to extend up to 35 days	1B 2B
Total knee replacement	2.0-3.0	At least 10 to 14 days Suggestion to extend up to 35 days	1B 2B
Hip fracture surgery	2.0-3.0	At least 10 to 14 days Suggestion to extend up to 35 days	1B 2B

*Edoxaban not FDA approved at time of writing of 2014 AHA/ACC guidelines.

**+/- aspirin while on warfarin followed with aspirin upon warfarin discontinuation

***LMWH is recommended over warfarin for post-op VTE prophylaxis (Grade 2C)⁵

¹ Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy For VTE Disease: Chest Guideline Published online January 07, 2016. doi:10.1016/j.chest.2015.11.026.

² 2014 AHA/ACC Guideline for the Management of Patients With Atrial Fibrillation. doi:10.1016/j.jacc.2014.03.022

³ 2020 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease. DOI: 10.1161/CIR.0000000000000923

⁴ Whitlock RP, et al. Antithrombotic and thrombolytic therapy for valvular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb;141(2 Suppl):e576S-e600S. doi: 10.1378/chest.11-2305. PMID: 22315272; PMCID: PMC3278057.

⁵ Prevention of VTE in Orthopedic Surgery Patients Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST 2012; 141(2)(Suppl):e278S–e325S

Length of Anticoagulation Treatment in VTE

Type of VTE	Recommendation
Acute VTE provoked by major or minor transient risk factors Examples of minor transient risk factors (present within 2 months before VTE): surgery with anesthesia <30 min., admission to hospital <3 days with an acute illness, estrogen therapy, pregnancy, confinement to bed outside hospital for at least 3 days with an acute illness, leg injury with reduced mobility, prolonged car or air travel)¹ Examples of major transient risk factors (present within 3 months before VTE): surgery with anesthesia >30 min., admission to hospital >3 days with an acute illness and bathroom only privileges, cesarean section, major trauma)¹	3 months (ACCP) (treatment phase)¹ 3-6 months (ASH) (primary treatment)² In patients with enduring risk factors (e.g. BMI ≥ 30, atherosclerotic cardiovascular disease, inflammatory disorders) following 3 months of anticoagulation, patients receiving apixaban 2.5mg twice daily for 12 months had substantially lower risk of recurrent VTE than placebo, with a low risk of major bleeding based on the HI-PRO trial.³
Acute VTE unprovoked by transient risk factors or provoked by persistent risk factors Examples of persistent risk factors: active CA, antiphospholipid syndrome, obesity¹	>3 months (ACCP) (extended phase)¹ >3-6 months (ASH) (secondary prevention)² • Reduced dose apixaban or rivaroxaban suggested over full dose apixaban or rivaroxaban^{1*} • If cannot use DOAC, VKA is suggested¹ Patient preference and predicted risk of VTE recurrence and bleeding should be considered before proceeding with extended therapy.¹

In all patients who receive extended therapy, the risk of VTE recurrence and bleeding risk should be periodically re-evaluated.¹


* Until more data are available for reduced dose DOACs in cancer-associated VTE, full DOAC dosing for 6 months is suggested (MAQI consortium)

¹Antithrombotic Therapy for VTE Disease Second Update of the CHEST Guideline and Expert Panel Report. CHEST 2021; 160(6):e545-e608

²American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv (2020) 4 (19): 4693–4738


³Piazza et al. HI-PRO Trial. Apixaban for Extended Treatment of Provoked Venous Thromboembolism. N Engl J Med. 2025 Sep 25;393(12):1166-1176. doi: 10.1056/NEJMoa2509426. Epub 2025 Aug 30. PMID: 40888734.

Length of treatment recommendations for idiopathic (unprovoked) VTE¹



¹Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. doi:10.1378/chest.11-2301

Treatment recommendations for provoked VTE after ≥3 months of initial treatment



HI-PRO defined enduring VTE risk factors

- Persistent immobility
- Obesity (BMI ≥30 kg/m²)
- Heart Failure (systolic, diastolic, combined)
- Chronic lung disease (COPD, asthma, interstitial lung disease)
- Chronic kidney disease (eGFR <60 mL/min/1.73 m²)
- Chronic inflammatory/autoimmune disorder (inflammatory arthritis, vasculitis, inflammatory bowel disease, or chronic infection)
- Atherosclerotic cardiovascular disease (coronary, cerebrovascular, or peripheral artery disease)

HI-PRO recurrent VTE and bleeding risk (over 12 months)

- Placebo: 10% symptomatic recurrent VTE; 0% major bleeding
- Apixaban 2.5 mg BID: 1.3% symptomatic recurrent VTE; 0.3% major bleeding

Piazza et al. HI-PRO Trial. Apixaban for Extended Treatment of Provoked Venous Thromboembolism. N Engl J Med. 2025 Sep 25;393(12):1166-1176. doi: 10.1056/NEJMoa2509426. Epub 2025 Aug 30. PMID: 40888734.

Return to [Things to Consider when Starting Patients on Warfarin](#)

Selection of Warfarin Starting Dose

Patient population	Initial dose
Most patients <i>Follow 5mg initiation nomogram after first two 5mg doses.</i>	5mg
Patients with acute VTE being treated in the outpatient setting and are low to moderate risk for bleeding ¹ <i>Follow 10 mg initiation nomogram after first two 10mg doses.</i>	10mg <i>Loading dose of 10mg daily for 2 days and then dosing based on INR measurements is a 2C recommendation in the latest ACCP guidelines for patients sufficiently health to be treated as outpatients where rapid attainment of therapeutic INR is required and considered safe³</i>
High bleeding risk patients (ex. elderly, malnourished, CHF, hepatic dysfunction, interacting drugs such as amiodarone)	Consider 2.5mg*

*MAQI² expert consensus

Selecting the initial starting dose involves assessing the patient's bleeding risk, need for rapid anticoagulation, and treatment environment. Two small randomized trials have compared 5mg and 10mg starting doses.

Study	Patient population	Methods	Results
Kovacs¹	Acute VTE, outpatient setting, concurrent LMWH treatment, 25% had CA, mean age 55 <u>Patients excluded:</u> baseline INR>1.4, thrombocytopenia, <18 years old, required hospitalization, high-risk for bleeding	201 patients randomized to receive either 5mg or 10mg initial dosing.	10mg superior to 5mg Patients with 10mg initial dosing reached first in-range INRs 1.4 days sooner and had similar rates of bleeding AEs and supratherapeutic INRs as patients started on 5mg.
Crowther²	Acute VTE, inpatient setting, most had concurrent heparin treatment, 1/3 had CA, mean age 66	53 patients randomized to receive either 5mg or 10mg initial dosing.	5mg just as good and possibly safer 5mg initial dosing resulted in therapeutic INRs as quickly as 10mg dosing with a trend toward less over-anticoagulation

An INR should be obtained within 3-5 days after starting warfarin to assess initial response

¹Kovacs M J et al. Comparison of 10-mg and 5-mg Warfarin Initiation Nomograms Together with Low-Molecular-Weight Heparin for Outpatient Treatment of Acute Venous Thromboembolism. Ann Intern Med. 2003;138:714-719.

²Crowther MA et al. A Randomized Trial Comparing 5-mg and 10-mg Warfarin Loading Doses. Arch Intern Med. 1999;159:46-8.

³Holbrook. Evidence-Based Management of Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. doi: 10.1378/chest.11-2295

For maintenance dosing and INR retesting algorithms, visit this [link](#).

Return to [Things to Consider when Starting Patients on Warfarin](#)

Factors Increasing or Decreasing Warfarin Sensitivity

When determining the appropriate starting dose of warfarin and making dose adjustments, it is important to consider if the patient may have increased or decreased sensitivity to warfarin.

Higher Sensitivity (Consider lower starting dose)	Lower Sensitivity (Consider higher starting dose)
Baseline INR >1.2	Baseline INR < 1.2
Advanced age (>65)	Younger age (<55) ¹
Female gender ²	Male gender ²
Low body weight (<110 pounds)	>200 pounds ²
Asian ancestry ³	African American ancestry ²
Recent surgery and blood loss ²	Diet high in Vitamin K ²
Comorbidities: CHF, renal disease, liver disease, and cancer ⁴	
Impaired nutritional status	
Alcohol abuse ⁴	
Concurrent use of medications known to increase INR, including amiodarone, acetaminophen, and many antibiotics and antifungals	
Acute illness (diarrhea, fever) ⁴	

¹Crowther MA et al. A Randomized Trial Comparing 5-mg and 10-mg Warfarin Loading Doses. Arch Intern Med. 1999;159:46-8.

² Absher. Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother. 2002 Oct;36(10):1512-7.

³ Dang. The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother. 2005 Jun;39(6):1008-12. Epub 2005 Apr 26. doi: 10.1345/aph.1E566

⁴ White. Patient factors that influence warfarin dose response. J Pharm Pract. 2010 Jun;23(3):194-204. doi: 10.1177/0897190010362177. Epub 2010 May 6. doi: 10.1177/0897190010362177

Warfarin Initiation Nomograms

Warfarin Initiation Nomogram (5mg starting dose, target INR range 2-3)¹

This algorithm was developed for in-patients started on **5mg with an INR target range of 2-3** and monitored with daily INRs. It may not be applicable to outpatient use in which daily INRs are not practical.


	INR	Dose
DAY 1		5 mg
DAY 2	<1.5 1.5 - 1.9 2.0 - 2.5 > 2.5	5 mg 2.5 mg 1 – 2.5 mg 0 mg
DAY 3	<1.5 1.5 - 1.9 2.0 - 3.0 > 3.0	5 - 10 mg 2.5 - 5 mg 0 - 2.5 mg 0 mg
DAY 4	< 1.5 1.5 - 1.9 2.0 - 3.0 > 3.0	10 mg 5 -7.5 mg 0 - 5 mg 0
DAY 5	< 1.5 1.5 - 1.9 2.0 - 3.0 > 3.0	10 mg 7.5 - 10 mg 0 - 5 mg 0
DAY 6	< 1.5 1.5 - 1.9 2.0 - 3.0 > 3.0	7.5 - 12.5 mg 5 - 10 mg 0 - 7.5 mg 0

¹Crowther. Ann Int Med, 127:333, 1997

For maintenance dosing and INR retesting algorithms, visit this [link](#).

Warfarin Initiation Nomogram (10mg starting dose, INR target range 2-3)²

This algorithm was developed and validated in acute VTE patients treated in the outpatient setting and receiving 10mg of warfarin for the first two days of treatment. Patients included in the study were deemed to not be high-risk for bleeds.³ Use in other patient populations, such as atrial fibrillation, has not been validated.



²Kovacs M J et al. Comparison of 10-mg and 5-mg Warfarin Initiation Nomograms Together with Low-Molecular-Weight Heparin for Outpatient Treatment of Acute Venous Thromboembolism. Ann Intern Med. 2003;138:714-719.3

Patients excluded from study: baseline INR>1.4, platelet count <50 K/uL, age < 18 years, required hospitalizations, considered high-risk for major bleeding (including interacting medications)

For maintenance dosing and INR retesting algorithms, visit this [link](#).

Initial VTE Treatment Setting (Hospital vs Home)

Guidelines recommend initial home treatment (or early discharge) of VTE patients if both clinical and home environment criteria are met.

Type/Location	Clinical criteria for initial treatment in home	Home environment criteria for initial treatment in home
Low-risk PE¹	- Clinically stable with good cardiopulmonary reserve, including: - age ≤80 - no hx of CA or chronic cardiopulmonary disease - HR <110, SBP ≥100 mm Hg, and O₂ ≥90% - No contraindications such as recent bleeding, severe liver/kidney disease, or thrombocytopenia	- Well-maintained living conditions - Strong support network - Ready access to medical care - Expected to be compliant - Access to phone
Acute DVT of leg²	No severe leg symptoms or important comorbidities	

¹Kearon C, Akl EA, Ornelas J, et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. CHEST 2016; 149(2):315-352

²Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians, Evidence-Based Clinical Practice Guidelines. CHEST 2012; 141(2)(Suppl):e419S–e494S

Another tool that can be used to determine the safety of outpatient treatment for PE is the scoring tool used in the HESTIA Study.

Criteria	Additional information for criteria
Is the patient hemodynamically unstable?	SBP <100mmHg with HR >100 bpm; condition requiring admission to an intensive care unit
Is thrombolysis or embolectomy necessary?	
Active bleeding or high risk of bleeding?	GI bleeding in the preceding 14 days, recent stroke (<4 weeks ago), recent operation (<2 weeks ago), bleeding disorder or thrombocytopenia (platelet count <75 × 10 ⁹ /L), uncontrolled hypertension (SBP >180 mmHg or DBP >110 mmHg).
More than 24h of oxygen supply to maintain oxygen saturation >90%	
Is pulmonary embolism diagnosed during anticoagulant treatment?	
Severe pain needing intravenous pain medication for more than 24h?	
Medical or social reason for treatment in the hospital for more than 24h (infection, malignancy, no support system)?	
Does the patient have a creatinine clearance of <30mL/min?	
Does the patient have severe liver impairment?	
Is the patient pregnant?	
Does the patient have a documented history of heparin-induced thrombocytopenia?	

If all of the answers were “no” (HESTIA score=0), patients were eligible for outpatient treatment.

J Thromb Haemost. 2011 Aug;9(8):1500-7. doi: 10.1111/j.1538-7836.2011.04388.x

Conversion from DOACs to Warfarin (Coumadin®)

Generic (Trade Name)	Package Insert Instructions (see below for 2018 ASH VTE guidelines [†] on transitioning)
Dabigatran (Pradaxa®)¹	- Adjust the starting time of warfarin based on creatinine clearance* as follows: - For CrCl ≥50 mL/min, start warfarin 3 days before discontinuing dabigatran. - For CrCl 30-50 mL/min, start warfarin 2 days before discontinuing dabigatran. - For CrCl 15-30 mL/min, start warfarin 1 day before discontinuing dabigatran. - For CrCl <15 mL/min, no recommendations can be made. *CrCl determined using Cockcroft-Gault formula and actual body weight: http://touchcalc.com/calculators/cg - Because dabigatran can increase INR, the INR will better reflect warfarin's effect only after dabigatran has been stopped for at least 2 days
Apixaban (Eliquis®)²	- Apixaban affects INR, so initial INR measurements during the transition to warfarin may not be useful for determining the appropriate dose of warfarin. - One approach is to discontinue apixaban and begin warfarin with a concomitant parenteral anticoagulant when the next dose of apixaban would have been due, discontinuing the parenteral anticoagulant when INR reaches goal range.+
Rivaroxaban (Xarelto®)³	- No clinical trial data are available to guide converting patients from rivaroxaban to warfarin. - Rivaroxaban affects INR, so INR measurements made during coadministration with warfarin may not be useful for determining the appropriate dose of warfarin. - One approach is to discontinue rivaroxaban and begin both a parenteral anticoagulant and warfarin at the time the next dose of rivaroxaban would have been taken.+
Edoxaban (Savaysa®)⁴	- For patients on 60 mg of edoxaban, reduce dose to 30 mg and begin warfarin concomitantly. - For patients on 30 mg of edoxaban, reduce dose to 15 mg and begin warfarin concomitantly. - During transition, INR should be done at least weekly just prior to daily dose of edoxaban (to minimize influence on INR). - Discontinue edoxaban once a stable INR ≥ 2.0 is achieved.

[†]For patients transitioning from DOAC to VKA for VTE, the 2018 ASH guideline panel *suggests* overlapping DOAC and VKA therapy until the INR is within range *over* using LMWH or UFH “bridging therapy”. To minimize DOAC interference with the INR, the ASH guideline panel suggests measuring the INR just before the next DOAC dose if overlapping DOAC therapy is used. ⁵ Note: Even at trough levels, the INR may still be elevated due to DOAC presence.

¹Pradaxa package insert (updated 12/2013): <http://bidocs.boehringer-ingenheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf>

²Eliquis® package insert (updated 1/2014): http://packageinserts.bms.com/pi/pi_eliquis.pdf

³Xarelto package insert (updated 1/2014): http://www.xareltohcp.com/sites/default/files/pdf/xarelto_0.pdf#zoom=100

⁴Savaysa® package insert: <http://dsi.com/prescribing-information-portlet/getPIContent?productName=Savaysa&inline=true>

⁵Witt DM, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018 Nov 27; 2(22): 3257–3291. doi: 10.1182/bloodadvances.2018024893

Most Clinically Relevant Warfarin-Drug Interactions

Potential of Drug Effect (Increased INR or increased bleed risk)	Inhibition of Drug Effect (Decreased INR)
Acetaminophen Allopurinol Amiodarone Amoxicillin Aspirin Azithromycin Bactrim(TMP-SMX) Cimetidine Ciprofloxacin Citalopram Clarithromycin Clopidogrel Cotrimoxazole Diltiazem Entacapone Erythromycin Fenofibrate Fish Oil Fluconazole Fluvastatin Gemcitabine Gemfibrozil Levofloxacin Lovastatin Metronidazole Miconazole (Suppository and Gel) Omeprazole Propafenone Propanolol Simvastatin SSRI's Tamoxifen Tetracycline Tramadol	Barbiturates Bosentan Carbamazepine Cigarette Smoking Chlordiazepoxide Ginseng Griseofulvin Mercaptopurine Multivitamin Supplement Nafcillin Phenobarbital Ribavirin Rifampin Secobarbital St. John's wort Phenytoin

For a more comprehensive list of potential drug, food, and dietary supplement interactions see Ageno et al. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
<http://journal.publications.chestnet.org/article.aspx?articleid=1159432>

Sources:

- Holbrook AM, et al. Systematic Overview of warfarin and its drug and food interactions. Arch Intern Med. 2005 May 23;165(10):1095-106. doi:10.1001/archinte.165.10.1095
- Badyal DK, Dadhich AP. Cytochrome P450 and drug interactions. Ind J Pharmacol 2001;33:248-59.
- Stading JA, Faulkner MA, Skrabal MZ. Effect of tobacco on INR.[Letter]. Am J HealthSystem Pharm 2007;64:805.

Return to [Things to Consider when Starting Patients on Warfarin](#)

Warfarin Patient Education Checklist

Completed	Topic
	What is anticoagulation and how does warfarin work?
	Why does patient need to start taking warfarin?
	How to take warfarin? (time of day, dose, weekly schedule, etc.)
	What is the expected duration of treatment?
	How is warfarin monitored? (INR testing, goal target range for patient, frequency of testing, etc.)
	What are the risks and side-effects of warfarin?
	What are the signs/symptoms of bleeding or clotting to watch for?
	What are the main factors influencing INR? (dietary intake of vitamin K, general health, activity level, alcohol, other medications/supplements, etc.)
	Ways to keep INR in range (consistent vitamin K content in diet, limit alcohol use, adhere to dosing instructions, etc.)
	What to do for missed doses?
	What are the drug-drug interactions to watch for? (including OTC and herbal supplements)
	What are the drug-food interactions to watch for?(Vitamin K rich foods, alcohol, etc.)
	What are some other necessary lifestyle changes? (no contact sports, fall avoidance, pregnancy)
	When and how to notify clinic? • s/sx of bleeding • medication/supplement changes • illness/changes in health status • Surgical procedures requiring warfarin interruption • Clinic contact information
	When to seek immediate medical attention?

Warfarin Education Material Links

Topic	
General warfarin (Coumadin®) information	MAQI Toolkit Medication Guide
Warfarin monitoring	Link
Diet	Link
Drug Interactions	Link
Reducing risk of complication	Link
Other patient resources	Link

Warfarin Maintenance Dosing and INR Recall Algorithms

These algorithms are intended to be used after the patient has gone through the initiation period and a chronic maintenance dose has been established. There may be valid clinical reasons to adjust doses outside these recommendations. Additionally, other algorithms may also be effective.

Target INR 2.5 (Range 2.0-3.0)

INR	≤1.5	1.51-1.99	2.00-3.00	3.01-4.00	4.01-4.99	5.00-10.00	>10.00
Dose Change	Increase 15% ¹	Increase 10% ¹	No change	Decrease 10% ¹	Hold for one day then decrease 10% ¹	Hold until INR therapeutic and then decrease by 15%* ¹	Hold until INR therapeutic and then decrease by 25%**
Next INR	within 7 days ²	7-14 days	See follow-up algorithm below	7-14 days	within 7 days ²	2-3 days	Daily until INR is within target range

Target INR 3.0 (Range 2.5-3.5)

INR	≤ 2.00	2.01-2.49	2.50-3.50	3.51-4.50	4.51-5.49	5.50-10.00	>10.00
Dose Change	Increase 15%	Increase 10%	No change	Decrease 10%	Hold for one day then decrease 10%	Hold until INR therapeutic and then decrease by 15%*	Hold until INR therapeutic and then decrease by 25%**
Next INR	4-8 days	7-14 days	See follow-up algorithm below	7-14 days	4-8 days	2-3 days	Daily until INR is within target range

Providers should consider other clinical factors before determining dose changes, including:

- recent trend in INR values
- dietary changes
- changes in health status
- changes in concomitant medications
- alcohol intake
- missed doses
- other possible explanations for out of range INRs

In some cases, a dose change may not be necessary if a probable cause for out of range INR is identified

* Additional measures: Attempt to identify reasons for high INR (e.g. drug interactions, change in diet, acute illness), assess for signs/symptoms of bleeding, counsel patient to avoid excessive physical activity and to report signs/symptoms of bleeding, and consider recommending additional servings of foods high in Vitamin K such as green, leafy vegetables.

**Measures in addition to the above: Administer oral vitamin K (2.5-5mg) if patient has no signs of bleeding. If patient has signs or symptoms of bleeding, send patient to ED immediately as more aggressive treatments may be required (i.e. IV vitamin K, fresh-frozen plasma, or prothrombin complex concentrate). Rapid reversal with four-factor prothrombin complex concentrate is suggested over plasma.²

For initial warfarin dosing, visit this [link](#).

INR Recall Algorithm	
# of consecutive in-range INRs	Repeat INR in
1	5-10 days
2	2 weeks
3	3 weeks
4	4 weeks

Algorithm may be accelerated for a previously stable patient with a single out-of-range INR.

If the patient has had multiple stable INRs and a consistent weekly warfarin dose for the past 12-week period, it is reasonable to begin waiting up to 12 weeks for the next INR.³ MAQI² recommends reserving the full 12-week recall interval for the most stable patients with low bleeding risk until more extended INR recall data is available. Patients should be reminded of the importance of notifying the clinic of changes in medications, diet, alcohol use, or general health as well as any signs/symptoms of bleeding that would warrant an earlier INR.

¹ Adapted from Van Spall HG, Wallentin L, Yusuf S, Eikelboom JW, Nieuwlaat R, Yang S, Kabali C, Reilly PA, Ezekowitz MD, Connolly SJ. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. *Circulation*. 2012 Nov 6;126(19):2309-16. doi: 10.1161/CIRCULATIONAHA.112.101808. Epub 2012 Oct 1.

² Ansell et al. Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. *J Thromb Thrombolysis* (2016) 41:187–205. DOI 10.1007/s11239-015-1319-y

³ Holbrook et al. Evidence-Based Management of Anticoagulant Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. doi: 10.1378/chest.11-2295

Warfarin Interruption and Bridging

Procedure Bleed Risk (see bleed risk of common procedures)	Low thromboembolic risk	Moderate thromboembolic risk	High thromboembolic risk ⁹
	AF: CHA ₂ DS ₂ -VASc score 1-4 or CHADS ₂ score of 0-2 (and no prior stroke or TIA) VTE: VTE >12 months ago MHV: Bileaflet aortic valve prosthesis without major risk factors for stroke ¹	AF: CHA ₂ DS ₂ -VASc 5-6 or CHADS ₂ score 3 or 4 VTE: VTE within past 3-12 months, recurrent VTE, non-severe thrombophilia ³ , active CA or recent hx of CA MHV: Mitral valve without additional stroke risk factors ¹ ; Bileaflet aortic valve prosthesis with major risk factors for stroke ¹	AF: CHA ₂ DS ₂ -VASc score ≥ 7 or CHADS ₂ score 5 or 6, recent stroke or TIA (< 3 months), or rheumatic valvular heart disease VTE: VTE < 3 months, severe thrombophilia ⁴ , antiphospholipid antibodies, associated with vena cava filter, associated with active CA with high VTE risk ⁵ MHV: Mitral valve with major risk factors for stroke ¹ ; caged-ball or tilting disc mitral/aortic valve prosthesis; recent (<3 months) stroke or TIA
Minimal	Do not interrupt ²	Do not interrupt ²	Do not interrupt ²
Low/Moderate/High	-Interrupt ⁶ -Do not bridge	-Interrupt ⁶ -Do not bridge	-Interrupt ⁶ -Bridging suggested ^{7,8} (2022 CHEST ^a) -Consider bridging in AF (if recent stroke/TIA or mechanical valve) (2023 ACC/AHA/ACCP ^c)

¹AF, prior stroke/TIA, prior valve thrombosis, rheumatic heart disease, hypertension, diabetes, congestive heart failure, age ≥ 75 years. ²Interruption may be appropriate if there is increased concern for bleeding due to patient factors (eg. dental extraction in a patient with poor dentition, a screening colonoscopy in a patient with history of polyps that may require resection, or coronary angiography with femoral access). ³heterozygous factor V Leiden or prothrombin gene mutation; ⁴eg. deficiency of protein C, protein S or antithrombin, homozygous factor V Leiden or prothrombin gene mutation or double heterozygous for each mutation, multiple thrombophilias; ⁵pancreatic cancer, myeloproliferative disorders, primary brain cancer, gastric cancer, and esophageal cancer; ⁶Aspirin recommended during interruption for non-cardiac surgeries in patients with prior PCI^d; ⁷ Address any reversible patient risk factors such as high INR or aspirin use, and consider bleed history before bridging; ⁸Bridging not suggested for colonoscopies with anticipated polypectomy; ⁹Consider delaying procedure, if possible, in high thrombotic risk patients with recent thromboembolism (within 3 months).

Decisions about interruption and bridging should only be made after assessment of individual patient- and procedure-related factors and discussions with the patient, management team, and proceduralist.

Adapted from:

^aDouketis et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline, Chest, Volume 162, Issue 5, 2022, Pages e207-e243, ISSN 0012-3692, <https://doi.org/10.1016/j.chest.2022.07.025>.

^bDoherty et al. 2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation. DOI: 10.1016/j.jacc.2016.11.024

^cJoglar, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation Circulation. 2023;148:e00–e00. DOI: 10.1161/CIR.0000000000001193

^dThompson, et. al. 2024 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery. doi.org/10.1161/CIR.0000000000001285

Warfarin interruption and resumption

Approach recommended by 2022 CHEST guidelines¹

Stopping	- In most patients, warfarin should be stopped 5 days prior to the procedure. - In select patients, longer periods of interruption may be necessary (eg. elderly with comorbidities, patients with very low dose warfarin requirements, and those with a high INRs).
Management immediately before procedure	- Assessment of INRs immediately prior to the procedure (eg. day before) is not routinely needed in most patients unless there are certain circumstances (eg. prior high INR or patients with known delayed warfarin elimination) - Routine use of vitamin K to treat pre-procedure elevated INRs is not recommended
Resumption	- Warfarin should be resumed within 24 hours after the procedure in most patients - Resumption may need to be delayed under some circumstances (eg. Inadequate hemostasis, potential need for additional intervention, or inability of patient to take oral meds)

Alternative approach from 2017 ACC Expert Consensus Pathway²

- Check INR 5-7 days prior to procedure
- Time the discontinuation of warfarin based on INR results according to the following table

INR result (5-7 days before procedure)	Supratherapeutic	Therapeutic	Subtherapeutic
When to start holding warfarin	At least 5 days before	5 days before	3-4 days before

- Recheck INR 24 hours before procedure to ensure it is at desired level*
- Warfarin can normally be restarted within the first 24 hours after the procedure at the patient's usual therapeutic dose.

*If INR still above desired level (eg. >1.5), consider low-dose oral vitamin K (1.0-2.5mg) and rechecking INR just prior to procedure.

¹Douketis et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline, Chest, Volume 162, Issue 5, 2022, Pages e207-e243, ISSN 0012-3692, <https://doi.org/10.1016/j.chest.2022.07.025>.

²Doherty et al. 2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation. DOI: 10.1016/j.jacc.2016.11.024

How to Bridge during Warfarin Interruption¹

Patient/ procedure factors	Bridging agent	When to start bridging agent prior to procedure	When to stop bridging agent prior to procedure	When to restart anticoagulants following procedure ^d	When to stop bridging agent
CrCl ≥30	LMWH	Start LMWH when INR goes below therapeutic range or after omitting 2-3 doses of warfarin (if INR not checked)	24 hours prior to the procedure. ^a	<u>Warfarin</u> : within 24 hours <u>LMWH</u> : at least 24 hours following low/moderate risk procedure; at least 48-72 hours in high bleed risk procedures ²	When INR becomes therapeutic
	UFH	Start UFH when INR goes below therapeutic range or after omitting 2-3 doses of warfarin (if INR not checked)	At least 4 hours prior to procedure and if aPTT is in normal range. ^b	<u>Warfarin</u> : within 24 hours <u>UFH</u> : at least 24 hours following procedure ² ; after 48-72 hours in high bleed risk procedures ¹	When INR becomes therapeutic
CrCl <30	UFH (recommended over LMWH) ^c	Start UFH when INR goes below therapeutic range or after omitting 2-3 doses of warfarin (if INR not checked)	At least 4 hours prior to procedure and if aPTT is in normal range. ^b	<u>Warfarin</u> : within 24 hours <u>UFH or LMWH</u> : at least 24 hours following procedure ² ; after 48-72 hours in high bleed risk procedures ¹	When INR becomes therapeutic
Heparin allergy or recent HIT	Follow local protocol	Follow local protocol	Follow local protocol	Follow local protocol	Follow local protocol

^a Half the total daily dose of LMWH the day prior to the procedure is suggested.²

^bIf aPTT is not in normal range, delay procedure and recheck aPTT every 2 hours until in normal range.

^cDosing guidance for LMWH is available for pts with a CrCl of 15 to 30mL/min, although caution is advised when using LMWH in this setting.

^dDelay restart of anticoagulation if complete hemostasis has not been achieved, if there are patient factors increasing bleed risk, or if there is potential for bleeding in a catastrophic location (eg. Intracranial, intraspinal)

¹Doherty et al. 2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation. DOI: 10.1016/j.jacc.2016.11.024

²Douketis et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline, Chest, Volume 162, Issue 5, 2022, Pages e207-e243, ISSN 0012-3692, <https://doi.org/10.1016/j.chest.2022.07.025>.

Example Schedule in Warfarin Patient Bridged with LMWH

Timing	Management
5 days before	Stop warfarin ¹
3 days before	Start LMWH ²
1 day before	Administer last dose of LMWH*
Procedure	
12-24 hrs after	Resume warfarin (if adequate hemostasis) ¹
At least 24 hrs after	Resume LMWH if low/mod bleed risk procedure ¹
2-3 days after	Resume LMWH if high bleed risk procedure ¹
4 days after	Check INR. If ≥ 2.0 on a single measure, discontinue LMWH ²

¹Chest. 2012;141(2_suppl):e326S-e350S. doi:10.1378/chest.11-2298

²J Thromb Haemost. 2016 May;14(5):875-85. doi: 10.1111/jth.13305

*Timing of last dose of LMWH should be considered. Last dose of LMWH should be given approx 24 hr prior to procedure time.

Decisions about bridging should only be made after assessment of individual patient and procedure-related factors and discussions with the patient, management team, and proceduralist.

Estimated Bleed Risk for Common Procedures¹

Bleed risk	Procedure	
Minimal ^a	- Minor dermatologic procedures (excision of basal and squamous cell skin cancers, actinic keratoses, and premalignant or cancerous skin nevi) - Ophthalmologic (cataract) procedures - Minor dental procedures (dental extractions, restorations, prosthetics, endodontics), dental cleanings, fillings - Pacemaker or cardioverter-defibrillator device implantation - Joint injections/aspirations²	
Low/moderate ^b	- Arthroscopy - Cutaneous/lymph node biopsies - Foot/hand surgery - Coronary angiography^d - GI endoscopy ± biopsy^e - Colonoscopy ± biopsy^e	- Abdominal hysterectomy - Laparoscopic cholecystectomy - Abdominal hernia repair - Hemorrhoidal surgery - Bronchoscopy ± biopsy
High ^c	- Major surgery with extensive tissue injury - Cancer surgery, especially solid tumor resection (lung, esophagus, gastric, colon, hepatobiliary, pancreatic) - Major orthopedic surgery, including shoulder replacement surgery - Reconstructive plastic surgery - Major thoracic surgery - Urologic or GI surgery, especially anastomosis surgery - Transurethral prostate resection, bladder resection, or tumor ablation - Nephrectomy, kidney biopsy	- Colonic polyp resection - Bowel resection - Percutaneous endoscopic gastrostomy placement, endoscopic retrograde cholangiopancreatography - Surgery in highly vascular organs (kidneys, liver, spleen) - Cardiac, intracranial, or spinal surgery - Any major operation (procedure duration > 45 minutes) - Neuraxial anesthesia^f - Epidural injections

^aProcedure can be safely done under full-dose anticoagulation (may consider holding DOAC dose day of procedure to avoid peak anticoagulant effects).

^bSome residual anticoagulant effect allowed (ie, two to three drug half-life interruptions pre-procedure).

^cNo residual anticoagulant effect at time of procedure (ie, four to five drug half-life interruptions pre-procedure).

^dRadial approach may be considered minimal bleed risk compared with femoral approach.

^eAmerican College of Gastroenterology suggests continuing warfarin for elective/planned endoscopic GI procedures, unless pt is undergoing an advanced procedure. Temporary interruption of DOACs are suggested in these procedures.³

^fIncludes spinal and epidural anesthesia or any other neuraxial (eg, pain management) intervention; consider not only absolute risk for major bleeding but potentially devastating consequences of epidural bleeding and associated lower limb paralysis.

Always discuss with proceduralist to determine bleed risk as the complexity of the procedure may vary case to case due to patient factors. For bleed risk information for additional procedures, see references.

¹Adapted from: Douketis et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline, Chest, Volume 162, Issue 5, 2022, Pages e207-e243, ISSN 0012-3692

²Kotecha et al. The Safety of Continued Oral Anticoagulation Therapy in Joint Injections and Aspirations: A Qualitative Review of the Current Evidence. JCR: Journal of Clinical Rheumatology 28(4):p 223-228, June 2022. DOI: 10.1097/RHU.0000000000001856

³Abraham, et al. American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period. The American Journal of Gastroenterology 117(4):p 542-558, April 2022. | DOI: 10.14309/ajg.000000000000162

Management of Patients Undergoing Elective Cardioversion

	AF for Greater than 48 hours	AF for 48 hour or Less
Starting anticoagulation	Therapeutic anticoagulation (warfarin with target INR 2-3, LMWH at treatment doses, or dabigatran) for at least three weeks prior to the scheduled procedure. (1B recommendation) ¹ Reasonable to use rivaroxaban or apixaban for 3 weeks prior	Suggest starting anticoagulation at presentation (LMWH or unfractionated heparin at full treatment doses) and proceeding to CV rather than delaying CV for 3 weeks of therapeutic anticoagulation or a TEE guided approach. (2C recommendation) ¹
Stopping anticoagulation after successful cardioversion	After at least 4 weeks of therapeutic anticoagulation (1B recommendation) ¹	Suggest therapeutic anticoagulation for at least 4 weeks rather than no anticoagulation, regardless of baseline stroke risk. (2C recommendation) ¹

LMWH=low Molecular Weight Heparin

TEE=trans esophageal echo

CV=cardioversion

¹Perioperative Management of Antithrombotic Therapy. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. doi:10.1378/chest.11-2298

Managing Patients on Medications that Interact with Warfarin

	Recommendation			
When should my patient have their INR drawn?	If taking a medication known to affect the INR, the patient should have a repeat INR within 3-5 days from the start date of the medication.			
What if my patient has a history of warfarin medication interaction or will begin taking a medication known to be “high-risk”?	Patients with a history of warfarin medication interaction, those at significant increase risk of bleeding complications, or who will be taking a medication known to be “high-risk” GIVE a preemptive dose adjustment (i.e. reduce the warfarin on the day that the ACS is notified that the medication has been started). In that scenario, repeat the INR within 3-5 days. See High-Risk table below for specific suggested preemptive dose adjustments			
What are the most common medications that can significantly <u>increase</u> the INRs?*	Acetaminophen Allopurinol Amiodarone Amoxicillin Aspirin Azithromycin Bactrim Cimetidine Ciprofloxacin Citalopram	Clarithromycin Clopidogrel Cotrimoxazole Diltiazem Entacapone Erythromycin Fenofibrate Fish Oil Fluconazole	Fluvastatin Gemcitabine Gemfibrozil Levofloxacin Lovastatin Metronidazole Miconazole (Suppository and Gel)	Omeprazole Propafenone Propranolol Simvastatin SSRI's Tamoxifen Tetracycline Tramadol
What are the most common medications that can significantly <u>reduce</u> the INR?*	Barbiturates Bosentan Carbamazepine Cigarette Smoking Chlordiazepoxide Ginseng Griseofulvin Mercaptopurine Multivitamin Supplement Nafcillin Phenobarbital Ribavarin Rifampin Secobarbital St. John's wort Phenytoin			

Adapted from University of Michigan Anticoagulation Service Guidelines

*For a more complete list of medications that increase, decrease, or have no effect on INRs, see: Holbrook AM, et al. Systematic Overview of warfarin and its drug and food interactions. Arch Intern Med. 2005 May 23;165(10):1095-106

High-Risk Medications		
Medication	Generic Name	Suggested Dose Change/Recheck*
Pacerone, Cordarone	Amiodarone	Decrease 30%, recheck in 7-10 days from start date
Arixtra	Fondaparinux Sodium	Increase dose by 10-20% and recheck INR every 2-3- days
Bactrim/Septra	Sulratrim, Trimoxazole, Trimethoprim	Decrease 30%, recheck in 7-10 days from start date
Biaxin	Clarithromycin	Decrease 30%, recheck in 7-10 days from start date
Diflucan	Fluconazole	Decrease 30%, recheck in 7-10 days from start date
Flagyl	Metronidazole	Decrease 30%, recheck in 7-10 days from start date
Rifampin	Rifadin, rimactane, rimycin, rofact	Increase dose by 10-20% and recheck INR every 2-3 days
Tricor	Fenofibrate, antara, triglide, lobibra	Decrease 30%, recheck in 7-10 days from start date
Xeloda	Methotrexate, capecitabine, cytarabine, fludarabine phosphate, fluorouracil, gemcitabine hydrochloride, hydroxyurea, mercaptopurine, pemetrexed	Decrease dose by 20-30% after checking INRs every 2-3 days, then decrease as needed

* These values represent expert opinion and have not been validated by randomized trials

Routine Follow-up Questions for Warfarin Patients

These questions should be asked at each PT/INR follow-up.

Assessment questions:
Is the patient taking warfarin as prescribed? (correct pill strength and schedule)
Does patient have any changes in general health status?
Any changes in diet, especially intake of vitamin K?
Has the patient started or stopped any prescription medications since last PT/INR?
Does the patient have any unusual bruising or bleeding?
Does the patient have any signs of clotting?
Has the patient had any ED visits or hospitalizations since the last PT/INR?
Has patients started or stopped any OTC vitamins, herbal supplements, dietary supplements, or pain relievers?
Does the patient have any procedures scheduled in the near future?
Does the patient have any travel plans that will interfere with monitoring?

Adapted from: Spectrum Health Medical Group. <http://www.spectrum-health.org/physicians/toolkits>

Patient self-management of warfarin

Patient self-management (PSM) is a warfarin management strategy in which patients or family members adjust the warfarin dose based on the INR. Based on evidence that shows decreased thrombotic events and mortality in patients using PSM compared to other management strategies, the 2018 American Society of Hematology Guidelines for VTE now recommend PSM in select patients.¹ However, PSM does require a large investment in training and equipment, and the cost-effectiveness is not clear at this time. Proper patient selection is key.

The AC Forum Centers of Excellence Resource Center (<https://acforum-excellence.org/Resource-Center/>) has an excellent PSM toolkit for providers and patients. This toolkit covers many important topics from basic information about PSM to specific tools for assessing patient eligibility and warfarin knowledge. The patient toolkit also includes education videos and competency assessments.

PSM toolkit for providers: https://rise.articulate.com/share/UqBL2hCC43e2Fhtw8eseiosvQX-bKP6a#

PSM toolkit for patients: https://rise.articulate.com/share/kVtvZxSlGB_DEieROFxPg-VdXyxoEDAp#

¹ American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Advances 2018 2:3257-3291; doi: <https://doi.org/10.1182/bloodadvances.2018024893>

Minor Bleeding

Minor bleeding, often referred to as nuisance bleeding, is a common problem in patients taking anticoagulants. Some of the most common types of minor bleeding include epistaxis; bleeding gums; prolonged bleeding from small cuts/scrapes; bruising; and small amounts of blood in the urine, stool, or sputum. It is estimated that about 15% of patients will have at least one minor bleeding event per year.¹ Over half of all ED visits for warfarin related bleeding are for minor bleeds.²

Recommendations:

- Educate patients that minor bleeding is normal, rarely an emergency, and not usually a reason to stop taking their anticoagulant.
 - Patients can be provided this pamphlet from the National Blood Clot Alliance for reassurance: <https://www.stoptheclot.org/wp-content/uploads/2014/02/Nuisance-Bleeding-Flyer.NBCA-copy.pdf>
- Patients should notify their provider if they have minor bleeding, or if minor bleeding becomes more frequent or heavy.
- Educate patients on how to prevent bleeding.
 - Do not participate in high-risk sports or activities
 - Always wear protective safety gear such as a bike helmet when biking or gloves when working in the garden or when using sharp tools
 - Use a soft toothbrush and an electric razor instead of blades
 - Use a humidifier and saline nose spray to prevent nasal dryness
 - Take steps to prevent constipation, such as maintaining a high fiber diet, drinking plenty of water, and getting plenty of exercise
- Provide the patient with information on how to manage minor bleeding in the home.
 - Handouts for dealing with epistaxis, minor skin injuries, and minor gastrointestinal and genitourinary bleeding: <http://www.anticoagulationtoolkit.org/patients>
 - Video on preventing and treating epistaxis in the home: [Nosebleeds in Patients on Blood Thinners](#)
 - Patients should keep a couple over the counter products on hand to help stop minor bleeding
 - Oxymetazoline nasal decongestant spray (eg. Afrin, Dristan) is very effective for epistaxis.
 - Hemostatic powders (eg. WoundSeal) are very effective at stopping bleeding from minor skin wounds.

¹BMJ. 2002 Oct 12; 325(7368): 828–831

²Arch Intern Med. 2010 Nov 22;170(21):1926-33. doi: 10.1001/archinternmed.2010.407.

Home Treatment for Dry Nose or Epistaxis

Dry Nose Treatment and Epistaxis Prevention ¹	
1. Make sure that patient's room or house is well humidified. ¹	
2. Use saline nasal spray 6-10 times/day (2 sprays in each nostril). ¹	
3. For additional moisturization ¹	
- For <u>short term</u> (less than 4-5 days) use a small amount of Vaseline Petroleum Jelly or A & D ointment or saline gel just inside the nose twice a day. - For <u>longer use</u>, obtain an over-the-counter water-based lotion (Eucerin, Neutrogena, or equivalent of cosmetic product) two times a day by placing a small amount into the front of the nose and sniffing. - For <u>intense short-term</u> moisturization (such as to treat problematic crusting/frequent bleeding) get a cotton ball greased with petroleum jelly or saline gel and insert into affected nostril at bedtime. Remove in the morning	
Epistaxis Treatment	
1. Sit or stand upright and lean slightly forward. This will prevent blood from going down the back of your throat. ²	
2. Apply pressure for 5 to 10 minutes. ²	
3. If a nosebleed lasts greater than 10 minutes, spray 2 sprays of Afrin in the nostril that is bleeding and pinch both nostrils tightly for 10 minutes head upright. ¹	
4. Do not blow your nose for 12 hours after the bleeding stops. This will allow a strong blood clot to form. ¹	
5. Avoid alcohol, hot liquids and hot or spicy foods for two days after the nosebleed. Alcohol and hot liquids in your mouth can dilate blood vessels in your nose and cause the bleeding to start again. ¹	
6. If bleeding persists or if there is concern about the amount of bleeding, notify your anticoagulation provider for further instructions. An urgent referral to an ENT physician may be necessary. If unable to reach anticoagulation provider, go to the nearest ER for further evaluation. ¹	

¹University of Michigan Anticoagulation Services' Dry Nose or Epistaxis Protocol

² University of Washington Anticoagulation Clinic

http://depts.washington.edu/anticoag/home/sites/default/files/Preventing_Treating_Nosebleeds_1_10.pdf

Refer patients to this video for a demonstration on how to prevent and stop epistaxis: [Nosebleeds in Patients on Blood Thinners](#)

Warfarin Reversal Guidelines

In patients with serious bleeding or highly elevated INRs, warfarin reversal may be required. Guidelines from various organizations are below.

CHEST Guidelines¹:

- For patients taking VKAs with INRs between 4.5 and 10 and with no evidence of bleeding, we suggest against the routine use of vitamin K. (Grade 2B)
- For patients taking VKAs with INRs >10.0 and with no evidence of bleeding, we suggest that oral vitamin K be administered. (Grade 2C)
- For patients with VKA-associated major bleeding, we suggest rapid reversal of anticoagulation with four-factor prothrombin complex concentrate (PCC) rather than with plasma. (Grade 2C)
 - Fresh Frozen Plasma (FFP) has the disadvantage of potential allergic reaction or transmission of infection, longer preparation time, and higher volume.
- We suggest the additional use of vitamin K 5 to 10 mg administered by slow IV injection rather than reversal with coagulation factors alone. (Grade 2C)

ASH Guidelines²:


- For patients with life-threatening bleeding during VKA treatment of VTE who have an elevated INR, the ASH guideline panel suggests using 4-factor prothrombin complex concentrates (PCCs) rather than fresh-frozen plasma (FFP) as an addition to cessation of VKA and IV vitamin K (conditional recommendation based on very low certainty in the evidence about effects)

AC Forum Guidance Statement³:

- For non-bleeding patients presenting with an elevated INR, we suggest the following:
 - For INRs 4.5-10
 - Withholding warfarin alone or in combination with 1.25–2.5 mg of oral vitamin K
 - For INRs >10
 - 2.5 mg of oral vitamin K
- For warfarin-related major bleeding we suggest rapid reversal of anticoagulation with 5–10 mg intravenous vitamin K and 4-factor non-activated PCC in conjunction with general supportive care and bleeding site interventions.

AHA/ASA ICH Guidelines⁴

- In patients with VKA-associated spontaneous ICH and INR ≥ 2.0 , 4-factor (4-F) prothrombin complex concentrate (PCC) is recommended in preference to fresh-frozen plasma (FFP) to achieve rapid correction of INR and limit hematoma expansion.
- In patients with VKA-associated spontaneous ICH, intravenous vitamin K should be administered directly after coagulation factor replacement (PCC or other) to prevent later increase in INR and subsequent hematoma expansion.
- In patients with VKA-associated spontaneous ICH with INR of 1.3 to 1.9, it may be reasonable to use PCC to achieve rapid correction of INR and limit hematoma expansion.



4F-PCC Dosing

4F-PCC (Kcentra®) is dosed based on units of Factor IX. The dose is determined by the patient's pretreatment INR and body weight.

FDA label dosing:

Pretreatment INR	2–<4	4–6	>6
Dose (units of Factor IX)/kg body weight	25	35	50
Maximum dose* (units of Factor IX)	Not to exceed 2500	Not to exceed 3500	Not to exceed 5000

*Dose is based on body weight up to but not exceeding 100 kg. For patients weighing more than 100 kg, maximum dose should not be exceeded.

4F-PCC is administered via intravenous infusion at a rate of 0.12 mL/kg/min (~3 units/kg/min) up to a maximum rate of 8.4 mL/min

Fixed-dose option:

Fixed dose options have been studied and are now supported by the 2017 ACC Guidelines.⁵

- 1000 units for any major bleed
- 1500 units for intracranial bleed

¹Holbrook, et al. Evidence-Based Management of Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST. Volume 141, Issue 2, Supplement, Pages e152S–e184S

²Witt, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018 Nov 27; 2(22): 3257–3291.

³Witt, D.M., Clark, N.P., Kaatz, S. et al. J Thromb Thrombolysis (2016) 41: 187. <https://doi.org/10.1007/s11239-015-1319-y>

⁴Greenberg et al. Stroke. 2022;53:00–00. DOI: 10.1161/STR.0000000000000407

⁵2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. JACC, Volume 70, Issue 24, 19 December 2017, Pages 3042–3067, ISSN 0735-1097, <https://doi.org/10.1016/j.jacc.2017.09.1085>

Resumption of Anticoagulation after Major Bleed

The decision to resume anticoagulation following a major bleeding event should be made based on numerous factors, including the location of bleed, factors contributing to the bleed, comorbid conditions, thromboembolic risk, and patient/family preferences. **Available evidence suggests that, in most cases, resumption of anticoagulation results in better patient outcomes.**¹ The following information can be used to help decide if anticoagulation should be resumed.

Available Guidelines:

- ASH Clinical Practice Guidelines: In VTE patients requiring long-term indefinite anticoagulation (mod-high risk of VTE recurrence) and not at high risk of recurrent bleeding, the ASH guideline panel suggests resumption of oral anticoagulation therapy within 90 days rather than discontinuation of therapy.¹

Clinical characteristics arguing for or against resuming anticoagulation after major bleed²

	Resume	Do not resume
Bleed-related characteristics		
-Known, correctable source	consider very strongly	
-Known, uncorrectable source	consider	
-Unknown source		consider
-Nonlobar ICH location	consider, particularly if strong indication for anticoagulation ³	
-Lobar ICH location		consider strongly, given relatively high risk of ICH recurrence ³
Indication for anticoagulation		
-Mechanical heart valve	consider very strongly	
-Idiopathic or recurrent VTE	consider very strongly	
-Provoked VTE, completed 3 mo of therapy		consider very strongly
-VTE + protein C/S or antithrombin deficiency or APLA syndrome	consider strongly	
-AF and prior history of stroke or higher CHADS ₂ or CHA ₂ DS ₂ -VASc score	consider very strongly	
-AF and lower CHADS ₂ or CHA ₂ DS ₂ -VASc score	consider	
-AF with no additional stroke risk factors		consider very strongly
Other characteristics		
-Previously unstable INR control despite adequate adherence		consider
-Renal failure		consider
-Poor prognosis, limited life expectancy		consider

- Other factors when considering anticoagulation resumption: concurrent use of antiplatelets or NSAIDs, INR value at time of bleed, and other comorbid conditions that increase bleed risk (eg. liver disease, hypertension, alcohol abuse)⁴
- Age alone should not be a reason to withhold anticoagulation after a bleeding event.⁴
- Although evidence related to anticoagulation resumption following major bleeding events is based on gastrointestinal or intracranial bleeds in patients taking warfarin, it is reasonable to extrapolate to other types of bleeds and to patients taking DOACs.²

When to resume anticoagulation after major bleed

Bleed location	When to resume
Gastrointestinal	Approx. 14 days ²
Intracranial	Within a month ²
Other	Once bleeding is resolved and hemostasis is normalized, consider restarting the anticoagulant after weighing risks and benefits of therapy vs. no therapy

Treatment strategies following bleeding in AF patients, specifically:

Major bleed:

- In patients with prior unprovoked bleeding, warfarin-associated bleeding, or at high risk of bleeding, we suggest using apixaban, edoxaban, or dabigatran 110 mg (where available) as all demonstrate significantly less major bleeding compared with warfarin.⁵

ICH, specifically:

- In patients with AF and high ischemic stroke risk, we suggest anticoagulation with a DOAC after acute spontaneous ICH (which includes subdural, subarachnoid, and intracerebral hemorrhages) after careful consideration of the risks and benefits (Ungraded consensus-based statement).⁵
- In patients with AF and very high thromboembolic risk (eg. rheumatic heart disease or mechanical heart valve), early resumption (1-2 weeks) is reasonable. In patients not considered to have very high thromboembolic risk, delayed resumption (4-8) weeks can be considered.⁶
- In patients with AF and conditions associated with high risk of recurrent ICH (eg. cerebral amyloid angiopathy), anticoagulation-sparing strategies (eg LAAO) may be considered.⁶

¹Witt, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Advances 2018 2:3257-3291; doi: <https://doi.org/10.1182/bloodadvances.2018024893>

²Witt. What to do after the bleed; resuming anticoagulation after major bleeding. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):620-624.

³Hemphill et al. 2015 AHA/ASA Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. DOI: 10.1161/STR.0000000000000069

⁴Colantino, Alison & Jaffer, Amir & Brotman, Daniel. (2015). Resuming anticoagulation after hemorrhage: A practical approach. Cleveland Clinic journal of medicine. 82. 245-256. 10.3949/ccjm.82a.14047.

⁵Lip, et al. Antithrombotic Therapy for Atrial Fibrillation-CHEST Guideline and Expert Panel Report. CHEST 2018; 154(5):1121-1201

⁶Joglar, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation Circulation. 2023;148:e00–e00. DOI: 10.1161/CIR.0000000000001193

DOAC Initiation Checklist

Task	Comments
Establish appropriate dose based on anticoagulant selected, indication and patient factors such as renal function.	See FDA approved anticoagulants for indication and dosing information.
Evaluate for medication or supplement interactions that may necessitate DOAC dose adjustment.	See DOAC drug interaction page
Evaluate renal function (Cockcroft-Gault equation to estimate CrCl) prior to DOAC initiation ¹ and establish a baseline for CBC and liver function ²	Use actual body weight in Cockcroft-Gault equation. Online calculator available at: http://touchcalc.com/calculators/cg
Establish clear expectations for length of treatment based on indication.	
Consider co-administration with a proton-pump inhibitor. ²	Proton-pump inhibitors do not appear to impact DOAC efficacy based on the clinical trials and may be helpful in reducing dyspepsia (dabigatran) and the risk of gastrointestinal bleeding ³
If converting from warfarin, see warfarin to DOAC conversion instructions .	
Provide comprehensive patient education.	See DOAC education topic checklist • If rivaroxaban, make sure patient knows to take with the largest meal of the day (typically the evening meal) • If dabigatran, make sure patient knows to take with a full glass of water, to store in the original package, and to not crush.
Establish follow-up plan.	Follow-up plan should include: • Who will the patient follow-up with? • How often will follow-up occur? • When is the next follow-up? • What will happen at the follow-ups? Follow-ups should check for: • compliance • thrombo-embolic events • bleeding events • Medication changes ○ P-gp inhibitors and inducers ○ P-gp/ CYP3A4 inhibitors and inducers ○ antiplatelets • need for blood sampling to recheck renal function, hepatic function, and CBC.²

¹ January C, Wann L, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. JACC. 2014. Doi: 10.1016/j.jacc.2014.03.022

²Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013. 15, 625-651. Doi: 10.1093/europace/eut083

³ Agewall et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J (2013) doi: 10.1093/eurheartj/ehu042

ICHECK'D Mnemonic for DOAC initiation

This tool was developed to help providers remember key factors in DOAC selection, dosing, and patient education.

ICHECK'D:

- **I= indication:** Why is the patient receiving the DOAC (Afib, VTE treatment, VTE prophylaxis, prevention of CV events) and is it a valid indication?
- **C= concomitant medications:** Is the patient receiving any inducers or inhibitors of cytochrome P450 enzyme subtype 3A4 (CYP3A4) or p-glycoprotein (P-gp)?
- **H= history** (medical history): Does the patient have a mechanical heart valve, moderate to severe mitral stenosis, pregnant/nursing, have hepatic impairment (Child-Pugh class B or higher)?
- **E= education** (for patient/care giver): Review risk of bleeding and procedures when dose may need to be held
- **C= compliance:** Missing or skipping doses may increase the risk of a blood clot since DOACs have a short half-life
- **K= kidney function:** Serum creatinine value needed prior to DOAC initiation and while receiving the DOAC in follow up.
 - **NVAF:** when creatinine clearance calculation is needed, Cockcroft-Gault formula using actual body weight should be utilized
 - **VTE:** only dabigatran is dosed using CrCl via Cockcroft-Gault formula (using actual weight)
- **D= dose correct for indication:** Monitor for any changes that may be needed based on above
 - **NVAF:** based on kidney function
 - **Acute VTE:** based on loading dose followed by maintenance dose

ICHECK'D (Adult patients only)	Apixaban (Eliquis)	Rivaroxaban (Xarelto)	Dabigatran (Pradaxa)	Edoxaban (Savaysa)
Indication	NVAF, VTE, VTE prophylaxis (knee and hip)	NVAF, VTE, VTE prophylaxis (knee and hip), CAD, PAD, VTE prophylaxis for acutely ill	NVAF, VTE, VTE prophylaxis (hip only)	NVAF, VTE
Concomitant medications (examples) (# = systemic)	All patients: • Avoid giving with: apalutamide, carbamazepine, fosphenytoin, phenytoin, rifampin, St. John's wort • If 5 mg or 10 mg twice daily, reduce 50% when given with: itraconazole[#], ketoconazole[#], ritonavir • If 2.5 mg twice daily, avoid giving with: itraconazole[#], ketoconazole[#], ritonavir NOTE: Although clarithromycin is a combined P-gp and strong CYP3A4 inhibitor, pharmacokinetic data suggest that no dose adjustment is necessary with concomitant administration. • There is limited data assessing the clinical significance of a possible interaction with strong CYP3A4 Inducers (enzalutamide, lumacaftor, mitotane, phenobarbital, primidone), consider patients thrombotic risk	All patients: • Avoid giving with: itraconazole[#], ketoconazole[#], ritonavir, apalutamide, carbamazepine, fosphenytoin, phenytoin, rifampin, St. John's wort • Avoid with CrCl 15 < 80 mL/min and receiving: dronedarone, erythromycin[#], verapamil NOTE: Although clarithromycin is a combined P-gp and strong CYP3A4 inhibitor, pharmacokinetic data suggest that no dose adjustment is necessary with concomitant administration. • There is limited data assessing the clinical significance of a possible interaction with strong CYP3A4 Inducers (enzalutamide, lumacaftor, mitotane, phenobarbital, primidone), consider patients thrombotic risk	All patients: • Avoid giving with apalutimide, carbamazepine, fosphenytoin, phenytoin, rifampin, St. John's wort NVAF: If CrCl 30-50 mL/min, and concomitant use of P-gp inhibitors* and dronedarone or ketoconazole[#], reduce dose to 75 mg twice daily. (No dose adjustment necessary for amiodarone, verapamil, quinidine, or clarithromycin). Avoid if CrCl < 30 mL/min with concomitant use of P-gp inhibitors* VTE and VTE prophylaxis: Avoid if CrCl < 50 mL/min with concomitant use of P-gp inhibitors* *P-gp inhibitors: amiodarone, azithromycin[#], carvedilol, clarithromycin, cyclosporine[#], daclatasvir, dronedarone, elagolix, eliglustat, erythromycin[#], flibanserin, fostamatinib, glecaprevir/pibrentasvir, itraconazole[#], ivacaftor, ketoconazole[#], lapatinib, ledipasvir, neratinib, osimertinib, propafenone, quinine, quinidine, ranolazine, ritonavir, rolapitant, simeprevir, velpatasvir, vemurafenib, verapamil	All patients: • Avoid giving with apalutamide, carbamazepine, fosphenytoin, phenytoin, rifampin, St. John's wort VTE: 30 mg daily** if taking verapamil, quinidine, azithromycin[#], clarithromycin[#], dronedarone, erythromycin[#], itraconazole[#], ketoconazole[#] • Use of other p-gp inhibitors has not been studied, but a similar dose reduction approach is likely reasonable.
History	All patients/all indications: contraindicated if mechanical heart valve, moderate to severe mitral stenosis, hepatic impairment (depending on DOAC and severity), pregnant or nursing, triple-positive antiphospholipid syndrome (APS)			
Education	All patients (and caregivers)/all indications: review risk for bleeding, signs and symptoms of bleeding, procedures when dose may need to be held			
Compliance	All patients (and caregivers)/all indications: reinforce that missing doses may increase the risk for a blood clot, discuss with caregiver for patients with dementia			
Kidney function	NVAF: serum creatinine value	NVAF: CrCl via Cockcroft-Gault formula using actual body weight	NVAF & VTE: CrCl via Cockcroft-Gault formula using actual body weight	NVAF: CrCl via Cockcroft-Gault formula using actual body weight

Dose	NVAF: 5 mg twice daily. Reduce to 2.5 mg twice daily if at least two of the following: age ≥ 80 years, body weight ≤ 60 kg or serum creatinine ≥ 1.5 mg/dL VTE: 10 mg twice daily x 7 days and then decrease to 5 mg twice daily Secondary VTE Prevention: may decrease to 2.5 mg twice daily after at least 6 months of treatment VTE prophylaxis: 2.5 mg twice daily for 12 days (knee) or 35 days (hip)	NVAF: 20 mg daily with evening meal. Reduce to 15 mg daily with evening meal if CrCl ≤50 mL/min or if on dialysis VTE: 15 mg twice daily with food x 21 days and then decrease to 20 mg daily with food. After 6 months of treatment may decrease to 10 mg daily. Avoid if CrCl < 15 mL/min or if on dialysis VTE prophylaxis: 10 mg daily for 12 days (knee) or 35 days (hip). Avoid if CrCl < 15 L/min or if on dialysis CAD: 2.5 mg BID in combination with daily ASA (75-100 mg) PAD: 2.5 mg BID in combination with daily ASA (75-100 mg). After lower extremity revascularization initiate once hemostasis is established. VTE prophylaxis for acutely ill*: 10 mg daily for 31-39 days. Avoid if CrCl < 15 mL/min or if on dialysis	NVAF: 150 mg twice daily. Reduce dose to 75 mg twice daily if CrCl 15-30 mL/min. Avoid if CrCl < 15 mL/min or on dialysis VTE: 150 mg twice daily after 5-10 days of parenteral anticoagulant. Avoid if CrCl ≤30 mL/min or on dialysis VTE prophylaxis (hip only): Initial = 110 mg x 1 then 220 mg daily for 28-35 days. Avoid if sCrCl ≤30 mL/min or on dialysis	NVAF: 60 mg daily if CrCl ≤ 95 mL/min. Reduce dose to 30 mg daily if CrCl is 15-50 mL/min. Avoid if CrCl > 95 mL/min or < 15 mL/min VTE: 60 mg daily after 5-10 days of parenteral anticoagulant. **Reduce dose to 30 mg daily if CrCl is 15-50 mL/min or body weight ≤60 kg or using any P-gp inhibitors listed above**. Not recommended if CrCl < 15 mL/min
-------------	---	---	---	--

DeCamillo, D.; Renner, E.: ICHECK'D: Mnemonic approach assists in caring for patients receiving direct oral anticoagulant. Cardiology Today 2018 Jan;21(1):12-13

AC Forum Direct Oral Anticoagulant (DOAC) Drug-Drug Interaction Guidance [2020-10-08-202155.pdf \(acforum-excellence.org\)](https://www.acforum-excellence.org/2020-10-08-202155.pdf)

#Prophylaxis of VTE in acutely ill medical patients at risk for VTE complications not at high risk of bleeding

Abbreviations: CrCl= creatinine clearance; P-gp= p-glycoprotein; NVAF= non-valvular atrial fibrillation; VTE= venous thromboembolism; CAD= coronary artery disease; PAD=peripheral arterial disease

Drug-Drug or Drug-Supplement interactions with DOACs

Although known to have fewer drug-drug interactions than warfarin, DOACs do have some important interactions with common drugs and natural supplements that clinicians and patients should be aware of. Some of these interactions result in clear contraindications while others may require a DOAC dose reduction as noted in package inserts. Some drugs/supplements may directly increase or decrease DOAC metabolism (inducers or inhibitors of CYP3A4 and/or P-gp), while others may increase bleed risk through their own antithrombotic activity.

- **CYP3A4 and/or P-gp Inducers decrease serum DOAC levels→increase thrombotic risk**
- **CYP3A4 and/or P-gp Inhibitors increase serum DOAC levels→increase bleed risk**
- **Consider the additive bleeding risk of drugs or natural supplements that have their own anticoagulant or antiplatelet effects.**
- See [DOAC information section](#) for more information on drug-drug interactions
 - Special notice regarding Paxlovid™: Paxlovid™ contains ritonavir, a known combined P-gp inhibitor and strong CYP3A4 inhibitor. Per DOAC package insert information, Paxlovid™ should be avoided in patients on rivaroxaban. In patients on apixaban 5 or 10mg twice daily, apixaban dose should be reduced by 50% during the 5-day duration of Paxlovid™. In patients already on apixaban 2.5mg, Paxlovid™ should be avoided. For dabigatran, Paxlovid™ should be avoided if CrCl<30 mL/min (AF) or CrCl <50 mL/min (VTE). For edoxaban in VTE, dose should be reduced to 30mg daily. If Paxlovid™ cannot be avoided, switching to an alternative anticoagulant or temporarily holding the DOAC during Paxlovid™ treatment may be an option based on patient thromboembolic risk and local policies.
- The AC Forum Centers of Excellence has a rapid resource with more information on specific drug-drug interactions for each DOAC. Look under “Drug info” at the following link: <https://acforum-excellence.org/Resource-Center/>
- The European Heart Rhythm Association has published a summary table of various drugs and their effect on plasma concentrations of each DOAC.² (See tables 3, 4, and 5 at <https://doi.org/10.1093/eurheartj/ehy136>)
- It is recommended to use more than one source for investigating possible drug-drug interactions (eg Lexi-Comp + Micromedix) and to check sources often for updates.¹

Examples of natural supplements with potential DOAC interactions*

P-gp Inducers ³	P-gp Inhibitors ³	CYP3A4 inducers ⁴	CYP3A4 inhibitors ^{4,5}
Genipin	Apigenin	Echinacea	Bearberry
Licorice root	Berberine	Ginkgo	Bitter orange
Mango	Black pepper extract	Liquorice	Black cohosh
Quercetin	Capsaicin	Rooibos	Cat's claw
Scutellaria	Curcumin	St. John's wort	Cranberry
Soy milk	Fisetin		Echinacea
St. John's wort	Ginkgo		Feverfew

Sucralose	Grape juice		Garlic
	Green Tea		Ginkgo
	Honokiol		Ginseng
	Lemonin		Goldenseal
	Notoginsenoside R1		Grapefruit
	Rutin		Green Tea
	Soybean extract		Milk thistle
			Resveratrol
			Rhodiola
			Saw palmetto
			Silymarin
			Silibinin
			St. John's wort
			Turmeric
			Valerian

Examples of natural supplements with antiplatelet or anticoagulant properties^{6,7,*}

Bromelain	Fish Oil	Green Tea	Selenium
Capsaicin	Garlic	L-arginine	Sweet birch bark
Chamomile	Ginger	Licorice	Taurine
Clove	Ginkgo biloba	Lycopene	Vitamin E
Coenzyme Q10	Ginseng	Magnesium	Willow bark
Dong quai	Glucosamine	Passion Flower	Wintergreen leaf
Feverfew	Grape seed extract	Policosanol	

***Note that many of these interactions are theoretical, have not been adequately studied, or may require consuming higher amounts than normally taken.**

- The Natural Medicines website has two helpful resources to identify potential interactions:
 1. Natural medicines database: <https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements.aspx>
 2. Interaction checker: <https://naturalmedicines.therapeuticresearch.com/tools/interaction-checker.aspx>
- If there is no clear indication for natural supplements that may affect DOAC serum concentration or that have antithrombotic effects, patients should be encouraged to discontinue them.

¹Vazquez, S. Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions. Blood. 2018;132(21):2230-2239. DOI 10.1182/blood-2018-06-848747

²Steffel J, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal (2018) 39, 1330–1393. [doi:10.1093/eurheartj/ehy136](https://doi.org/10.1093/eurheartj/ehy136)

³Di Minno A, et al. Old and new oral anticoagulants: Food, herbal medicines and drug interactions. Blood Reviews. Volume 31, Issue 4, July 2017, Pages 193-203. <https://doi.org/10.1016/j.blre.2017.02.001>

⁴ Williamson E, et al. Herbal Medicine Interactions.

https://www.stonybrookmedicine.edu/sites/default/files/herbal_medicines_interactions-1.pdf

⁵Sprouse A, Van Breemen R. Pharmacokinetic Interactions between Drugs and Botanical Dietary Supplements. *Drug Metab Dispos.* 2016 Feb; 44(2): 162–171. doi: 10.1124/dmd.115.066902

⁶ Samuels N. Herbal Remedies and Anticoagulant Therapy. *Thromb Haemost.* 2005. 93:3-7.

⁷Stanger M, et al. Anticoagulant activity of select dietary supplements. *Nutrition Reviews.* Vol. 70(2):107–117. doi:10.1111/j.1753-4887.2011.00444.x

Conversion from Warfarin (Coumadin®) to DOACs

Generic (Trade Name)	Instructions
Dabigatran (Pradaxa®) ¹	Discontinue Warfarin (Coumadin®) and begin dabigatran when INR is below 2.0
Apixaban (Eliquis®) ²	Discontinue Warfarin (Coumadin®) and begin Apixaban (Eliquis®) when the INR is below 2.0
Rivaroxaban (Xarelto®) ³	Discontinue warfarin (Coumadin®) and begin Rivaroxaban (Xarelto®) when the INR is below 3.0 to avoid periods of inadequate anticoagulation (same instructions for A-fib and VTE).
Edoxaban (Savaysa®) ⁴	Discontinue warfarin and begin edoxaban when the INR is ≤ 2.5.

Conversion from Parenteral Anticoagulants to DOACs

Generic (Trade Name)	Low Molecular Weight Heparin (LMWH)	Unfractionated Heparin
Dabigatran (Pradaxa®) ¹	Discontinue LMWH and start Pradaxa® 0-2 hours before the time of the next scheduled administration of LMWH	Stop the infusion and start Pradaxa® at the same time
Apixaban (Eliquis®) ²	Discontinue LMWH and start Eliquis® at the time of the next scheduled administration of LMWH	Stop the infusion and start Eliquis® at the same time
Rivaroxaban (Xarelto®) ³	Discontinue LMWH and start Xarelto® 0-2 hours before the time of the next scheduled evening administration of LMWH	Stop the infusion and start Xarelto® at the same time
Edoxaban (Savaysa®) ⁴	Discontinue LMWH and start Savaysa® at the time of the next scheduled administration of LMWH	Discontinue the infusion and start SAVAYSA® 4 hours later

¹Pradaxa® [package insert](#)

²Eliquis® [package insert](#)

³Xarelto® [package insert](#)

⁴Savaysa® [package insert](#)

DOAC Education Checklist

Completed	Topic
	What is anticoagulation and how do DOACs work?
	If on warfarin in the past, how are DOACs different from warfarin? <i>No INR monitoring required, no need for frequent dose adjustments, no Vit. K interactions, much quicker onset/offset of action, likely more expensive</i>
	Why does patient need to start taking a DOAC?
	What is the expected duration of treatment?
	How to take the DOAC? (dose, frequency, timing, with food?) <i>Xarelto® must be taken with evening meal (or largest meal of day). Pradaxa® can be taken with or without food but should be taken with a full glass of water. Pradaxa® cannot be crushed. Eliquis® can be taken with or without food. Savaysa® can be taken with or without food</i>
	Why is it important not to skip doses? <i>Very rapid offset-increased risk for clots</i>
	What to do about missed doses?
	What are the signs/symptoms of bleeding or clotting to watch for? <i>Be sure to cover signs/symptoms of GI and intracranial bleeds.</i>
	What medications can increase risk of bleeding? <i>(ex. ASA, NSAIDs, other anticoagulants such as warfarin and heparin, SSRIs)</i>
	What are other drug-drug interactions to watch for? <i>P-gp and CYP3A4 inhibitors and inducers (ex. rifampin, carbamazepine, phenytoin, St. John's wort, dronedarone, ketoconazole, verapamil, amiodarone, clarithromycin, itraconazole, and ritonavir)</i>
	What kind of lab monitoring will need to be done and how often? <i>Ex. kidney function, liver function, CBC</i>
	What to do about taking DOACs around procedures/surgeries?
	How to store DOACs? <i>Pradaxa® must be kept in its original packaging</i>
	What are some other necessary lifestyle changes? <i>avoid contact sports, falls, pregnancy, etc.</i>
	When and how to notify clinic? • <i>s/sx of minor bleeding</i> • <i>medication changes</i> • <i>changes in health status, especially changes in kidney function or pregnancy</i> • <i>procedures in which DOAC will be held</i> • <i>changes in insurance or financial status that may impact ability to get refills</i>
	When to seek immediate medical attention? • <i>s/sx of serious or uncontrolled bleeding</i>

DOAC Patient Education Materials

Generic (Trade Name)	MAQI Toolkit Link	Drug Company Medication Guides
Dabigatran (Pradaxa®)	Link	Link
Apixaban (Eliquis®)	Link	Link
Rivaroxaban (Xarelto®)	Link	Link
Edoxaban (Savaysa®)	Link	Link

Routine Follow-up Checklist for DOAC Patients

	Interval	Comments
Assess compliance	Each visit	- Instruct patient to bring remaining medication: note and calculate average adherence - Re-educate on importance of strict intake schedule - Inform about compliance aids (special boxes; smartphone applications, etc.) Dabigatran must remain in original packaging
Assess for thrombo-embolism	Each visit	- Systemic circulation (TIA, stroke, peripheral) - pulmonary circulation
Assess for bleeding	Each visit	- If minor (nuisance) bleeding, are preventive measures possible? (eg. PPI, saline nose spray, etc.). Motivate patient to diligently continue anticoagulation. - If bleeding with impact on quality-of-life or with significant risk, is prevention possible? (consider changing anticoagulant)
Assess for other side effects	Each visit	Assess for link to DOAC and decide whether to continue, temporarily stop, or change to different anticoagulant
Assess for new co-medications	Each visit	- Assess for P-gp inhibitors/inducers (if on dabigatran or edoxaban) or dual P-gp/CYP3A4 inhibitors (if on rivaroxaban or apixaban) - Assess for other medications that may increase risk of bleeding such as anti-platelets NOTE: DOAC dose adjustments may be required if patient starts taking interacting medications (see drug interaction table).
Assess labs	Lab	Interval¹
	Renal function	Every 1-2 months (CrCL <30 mL/min) Every 3 months (CrCL 30-59 mL/min) Every 6 months (CrCL >60mL/min)
	Liver function	Every 1-2 months (Severe liver disease: Child-Pugh C) Every 3 months (Moderate liver disease: Child-Pugh B) Every 6 months (Mild liver disease: Child-Pugh A) Every 12 months (No liver disease)
	Hemoglobin/hematocrit	Every 3 months (High bleeding risk: HAS-BLED score ≥3) Every 6 months (Low/Mod bleeding risk HAS-BLED score 0-2)
	NOTE: Declining renal function may require a DOAC dose adjustment (see FDA approved anticoagulants for dosing information). Edoxaban is contraindicated for atrial fibrillation in patients with CrCl >95.	

*CrCl determined using Cockcroft-Gault formula and actual body weight

Adapted from: Heidbuchel et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013. 15, 625-651. Doi: 10.1093/europace/eut083

¹Joglar, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation Circulation. 2023;148:e00–e00. DOI: 10.1161/CIR.0000000000001193


DOAC Management Plan Flowchart

UW Medicine

MANAGEMENT PLAN FOLLOWING INITIATION OF DIRECT ORAL ANTICOAGULANTS (DOACs) APIXABAN/DABIGATRAN/EDOXYBAN/RIVAROXABAN

CONSIDERATIONS AT TIME OF INITIATION

- Confirm appropriateness of therapy
- Obtain baseline labs (CBC/LFTs/SCr) and calculate creatinine clearance (CrCl) using Cockcroft-Gault
- Conduct medication review to assess potential for drug interactions (see <https://depts.washington.edu/anticoag>)
- Review indication for therapy and provide education to patient, supplemented by written materials



UW Medicine Anticoagulation Services

June 2015

(c) 2015 University of Washington. Used with Permission

DOAC Interruption and Bridging

Procedure bleed risk	DOAC	Interruption/bridging recommendation
Minimal	apixaban, edoxaban, rivaroxaban	Do Not interrupt (time procedure at DOAC trough level, if possible ¹)
	dabigatran	Do Not interrupt (time procedure at DOAC trough level, if possible ¹)
Low/moderate	apixaban, edoxaban, rivaroxaban	-Interrupt for 1 day * -Do not bridge
	dabigatran	-Interrupt for 1 day (CrCl≥50 mL/min)* -interrupt for 2 days (CrCl<50 mL/min)* -Do not bridge
High	apixaban, edoxaban, rivaroxaban	-Interrupt for 2 days *,† -Do not bridge
	dabigatran	-Interrupt for 2 days (CrCl≥50 mL/min) *,† -interrupt for 4 days (CrCl<50 mL/min) *,† -Do not bridge

Decisions about DOAC interruption should only be made after assessing patient- and procedure-specific factors and discussions with patient, management team, and proceduralist.

*A longer duration of interruption may be required in some special cases, irrespective of the DOAC used. This may include patients with severe renal insufficiency (CrCl < 30 mL/min), impaired hepatic function, or patients taking CYP3A4 or P-glycoprotein inhibitors which may interfere with DOAC clearance.

†See table on next page for suggested length of interruption for patients undergoing regional anesthesia per 2025 ASRA guidelines

DOAC interruption and restart¹

DOAC	Procedure Bleed Risk (see next page for examples)	Peri-Procedural DOAC use									
		Day -5	Day -4	Day -3	Day -2	Day -1	Day of proc.	Day +1	Day +2	Day +3	Day +4
Rivaroxaban, apixaban, edoxaban	High [†]								Resume day 2 or 3 (1 st dose 48-72 hrs post-procedure)		
	Low/Mod							1 st dose ≥24 hrs post-procedure			
Dabigatran (CrCl ≥50 mL/min ^a)	High [†]								Resume day 2 or 3 (1 st dose 48-72 hrs post-procedure)		
	Low/Mod							1 st dose ≥24 hrs post-procedure			
Dabigatran (CrCl <50 mL/min ^a)	High [†]								Resume day 2 or 3 (1 st dose ≥48 hrs post-procedure)		
	Low/Mod							1 st dose ≥24 hrs post-procedure			

^aCrCl calculated using Cockcroft-Gault and actual body weight.

DOAC management decisions should be individualized, considering patient and procedure factors in consultation with the patient, care team, and proceduralist. If feasible, delay the procedure to address any risks. Some cases—such as severe renal insufficiency (CrCl < 30 mL/min), impaired liver function, or use of CYP3A4/p-glycoprotein inhibitors—may require longer hold times, regardless of the DOAC used.

[†]Length of interruption prior to neuraxial block or deep plexus/peripheral block per ASRA guidelines²

DOAC	High dose (therapeutic dose)	Low dose (prophylactic dose)
Apixaban	≥72 hours	≥36 hours
Edoxaban	≥72 hours	N/A
Rivaroxaban	≥72 hours	≥24 hours (≥30 hours if CrCl <30 mL/min)
Dabigatran	≥72 hours (CrCl ≥50 mL/min) 120 hours (CrCl 30–49 mL/min) Procedure not recommended if CrCl <30 mL/min unless plasma level <30 ng/mL	≥48 hours

High dose DOACs can be resumed after at least 24 hours post needle/catheter removal. Low dose DOACs can be resumed after at least 6 hours post needle/catheter removal.²

¹Douketis et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline, Chest, Volume 162, Issue 5, 2022, Pages e207-e243, ISSN 0012-3692, <https://doi.org/10.1016/j.chest.2022.07.025>.

²Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fifth Edition). Reg Anesth Pain Med. 2025 Oct 17:rapm-2024-105766. doi: 10.1136/rapm-2024-105766. Epub ahead of print. PMID: 39880411

Estimated Bleed Risk for Common Procedures¹

Bleed risk	Procedure	
Minimal ^a	- Minor dermatologic procedures (excision of basal and squamous cell skin cancers, actinic keratoses, and premalignant or cancerous skin nevi) - Ophthalmologic (cataract) procedures - Minor dental procedures (dental extractions, restorations, prosthetics, endodontics), dental cleanings, fillings - Pacemaker or cardioverter-defibrillator device implantation - Joint injections/aspirations²	
Low/moderate ^b	- Arthroscopy - Cutaneous/lymph node biopsies - Foot/hand surgery - Coronary angiography^d - GI endoscopy ± biopsy^e - Colonoscopy ± biopsy^e	- Abdominal hysterectomy - Laparoscopic cholecystectomy - Abdominal hernia repair - Hemorrhoidal surgery - Bronchoscopy ± biopsy
High ^c	- Major surgery with extensive tissue injury - Cancer surgery, especially solid tumor resection (lung, esophagus, gastric, colon, hepatobiliary, pancreatic) - Major orthopedic surgery, including shoulder replacement surgery - Reconstructive plastic surgery - Major thoracic surgery - Urologic or GI surgery, especially anastomosis surgery - Transurethral prostate resection, bladder resection, or tumor ablation - Nephrectomy, kidney biopsy	- Colonic polyp resection - Bowel resection - Percutaneous endoscopic gastrostomy placement, endoscopic retrograde cholangiopancreatography - Surgery in highly vascular organs (kidneys, liver, spleen) - Cardiac, intracranial, or spinal surgery - Any major operation (procedure duration > 45 minutes) - Neuraxial anesthesia^f - Epidural injections

^aProcedure can be safely done under full-dose anticoagulation (may consider holding DOAC dose day of procedure to avoid peak anticoagulant effects).

^bSome residual anticoagulant effect allowed (ie, two to three drug half-life interruptions pre-procedure).

^cNo residual anticoagulant effect at time of procedure (ie, four to five drug half-life interruptions pre-procedure).

^dRadial approach may be considered minimal bleed risk compared with femoral approach.

^eAmerican College of Gastroenterology suggests continuing warfarin for elective/planned endoscopic GI procedures, unless pt is undergoing an advanced procedure. Temporary interruption of DOACs are suggested in these procedures³

^fIncludes spinal and epidural anesthesia or any other neuraxial (eg, pain management) intervention; consider not only absolute risk for major bleeding but potentially devastating consequences of epidural bleeding and associated lower limb paralysis.

Always discuss with proceduralist to determine bleed risk as the complexity of the procedure may vary case to case due to patient factors. For bleed risk information for additional procedures, see references.

¹Adapted from: Douketis et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline, Chest, Volume 162, Issue 5, 2022, Pages e207-e243, ISSN 0012-3692

²Kotecha et al. The Safety of Continued Oral Anticoagulation Therapy in Joint Injections and Aspirations: A Qualitative Review of the Current Evidence. JCR: Journal of Clinical Rheumatology 28(4):p 223-228, June 2022. DOI: 10.1097/RHU.0000000000001856

³Abraham, et al. American College of Gastroenterology-Canadian Association of Gastroenterology Clinical Practice Guideline: Management of Anticoagulants and Antiplatelets During Acute Gastrointestinal Bleeding and the Periendoscopic Period. The American Journal of Gastroenterology 117(4):p 542-558, April 2022. | DOI: 10.14309/ajg.0000000000001627

DOAC Discontinuation and Resumption around Interventional Pain Procedures

Drug	ASRA Guidelines* ¹		CHEST Guidelines** ²	
	Discontinue prior to procedure	Resume after procedure	Discontinue prior to procedure	Resume after procedure
Dabigatran	4 days 5-6 days (if renal disease)	24 hours	2 days (CrCl ≥ 50 mL/ min) 4 days (CrCl < 50 mL/ min)	48-72 hours
Apixaban	3 days	24 hours	2 days	48-72 hours
Rivaroxaban	3 days	24 hours	2 days	48-72 hours
Edoxaban	3 days	24 hours	2 days	48-72 hours

* The ASRA recommendations are for intermediate and high bleed risk interventional pain procedures. For low-risk procedures, a shared assessment, risk stratification, and management decision in conjunction with the treating physician(s) should guide treatment decision. A 2 half-life interval may be considered for low-risk procedures. See table below for ASRA risk stratification.

**The CHEST recommendations are based on their criteria for high bleed risk pain procedures, which include spinal and epidural anesthesia procedures or any other neuraxial pain management procedure.

For guidelines on DOAC periprocedural management around neuraxial blocks or deep plexus/peripheral blocks, specifically, see [table above](#).

ASRA Procedure Bleed Risk Categories ¹		
High-Risk Procedures	Intermediate-Risk Procedures**	Low-Risk Procedures**
- Spinal cord stimulation trial and implant - Dorsal root ganglion stimulation - Intrathecal catheter and pump implant - Vertebral augmentation (vertebroplasty and kyphoplasty) - Percutaneous decompression laminotomy - Epiduroscopy and epidural decompression	- Interlaminar ESIs (C, T, L, S) - Transforaminal ESIs (C, T, L, S) - Cervical† facet MBNB and RFA - Intradiscal procedures (C, T, L) - Sympathetic blocks (stellate, T, splanchnic, celiac, lumbar, hypogastric) - Trigeminal and sphenopalatine ganglia blocks	- Peripheral nerve blocks - Peripheral joints and musculoskeletal injections - Trigger point injections including piriformis injection - Sacroiliac joint injection and sacral lateral branch blocks - Thoracic and lumbar facet MBNB and RFA - Peripheral nerve stimulation trial and implant - Pocket revision and implantable pulse generator/intrathecal pump replacement

C indicates cervical; L, lumbar; MBNB, medial branch nerve block; RFA, radiofrequency ablation; S, sacral; T, thoracic.

**Patients with high risk for bleeding (eg, old age, history of bleeding tendency, concurrent uses of other anticoagulants/antiplatelets, liver cirrhosis or advanced liver disease, and advanced renal disease) undergoing low- or intermediate-risk procedures should be treated as intermediate or high risk, respectively. Patients with high risk for bleeding may include old age, history of bleeding tendency, concurrent uses of other anticoagulants/antiplatelets, liver cirrhosis or advanced liver disease, and advanced renal disease.

¹Narouze S, Benzon HT, Provenzano D, Buvanendran A, De Andres J, Deer T, Rauck R, Huntoon MA. Interventional Spine and Pain Procedures in Patients on Antiplatelet and Anticoagulant Medications (Second Edition): Guidelines From the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med. 2018 Apr;43(3):225-262. doi: 10.1097/AAP.0000000000000700. PMID: 29278603.

²Douketis et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline, Chest, Volume 162, Issue 5, 2022, Pages e207-e243, ISSN 0012-3692

Measuring Anticoagulation Effect of DOACs¹

Test	Availability*	Apixaban	Dabigatran	Edoxaban	Rivaroxaban
PT	Widely available	Not useful	Not useful	Not useful ³	Not useful ³
dPT	Not widely available	Data not available	Data not available		Data not available
mPT	Not widely available	Useful for qualitative assessment	Data not available		Data not available
APTT	Widely available	Not useful	Not useful ³		Not useful
TT	Widely available, but turnaround time may vary	Not useful	Useful for qualitative assessment but may be abnormal even at clinically insignificant concentrations. Normal TT excludes clinically relevant levels. ³		Not useful
dTT/HEMOCL OT	Not widely available	Not useful	Useful for quantitative assessment		Not useful
Anti-FXa assay	Widely available, but turnaround time may vary. Assays must be set up for each Xa drug. Assays for heparin or LMWH cannot be used.	Useful for quantitative assessment Normal result excludes clinically relevant levels ²	No effect	Useful for quantitative assessment Normal result excludes clinically relevant levels ²	Useful for quantitative assessment Normal result excludes clinically relevant levels ²
Anti-FIIa assay	Not widely available	No effect	Useful for quantitative assessment		No effect
Ecarin anti-FIIa assay	Not widely available	No effect	Useful for quantitative assessment		No effect

APTT, activated partial thromboplastin time; dPT, dilute prothrombin time; dTT, dilute thrombin time; mPT, modified prothrombin time; PT, prothrombin time; TT, thrombin time.

Qualitative=assess if drug is present, Quantitative=assess drug concentration

*Assays or reagents may not be approved for patient care purposes; check with your local laboratories before ordering the test.

¹Adapted from: Garcia D. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost. 11: 245–252. DOI: 10.1111/jth.12096

²Cuker et al. J Am Coll Cardiol 2014;64:1128. doi:10.1016/j.jacc.2014.05.065

³Shaw et al. Coagulation assays and direct oral anticoagulant levels among patients having an elective surgery or procedure. J Thromb Haemost. 2022 Dec;20(12):2953-2963. doi: 10.1111/jth.15901. Epub 2022 Oct 18. PMID: 36200348.

DOAC Bleeding Management (v1.5)

Determine Bleed Severity	- Determining bleed severity is a key step in making treatment decisions. - Bleeds can be classified into major and non-major based on several clinical factors. If one or more of the following factors apply, the bleed should be considered major.			For additional information , visit www.anticoagulationtoolkit.org		
	Bleeding in critical site (examples below)		Hemodynamic instability (examples below)		Overt bleeding with either:	
	- Central nervous system bleeds (intracranial, spinal, intraocular) - Pericardial tamponade - Airway, including posterior epistaxis - Hemothorax		- Intra-abdominal - Retropertitoneal - Intra-articular - Intra-muscular		- Elevated heart rate - Decrease in SBP >40 mm Hg - Mean arterial pressure (intra-arterial) <65 mm Hg - SBP <90 mm Hg - Orthostatic blood pressure changes - Urine output <0.5 mL/kg/hr	- Hemoglobin drop of ≥2 g/dL or - Administration of ≥2 U of packed RBCs
Assess for Clinically Relevant Drug Levels	- If last dose taken at least 24 hr ago in patients with normal renal function, drug levels probably not clinically relevant.¹ - If patient taking dabigatran, a TT can be used to rule out clinically relevant drug levels. Specialized tests can quantify drug levels. - If apixaban, edoxaban, rivaroxaban, or betrixaban, anti-Xa is the preferred test and can be used to rule out relevant drug levels or quantify levels. Don't wait for results before administering reversal agents in life-threatening bleeds!					
		Specialized Test	Drug Level Interpretation	General Test	Drug Level Interpretation	
	Dabigatran	dTT, ECT, ECA	Normal: not clinically relevant Results correlate with drug level	TT	Normal: not clinically relevant Prolonged: may/may not be clinically relevant	
				aPTT	Normal: likely indicates lower drug level but can't exclude drug presence Prolonged: clinically relevant	
Apixaban Betrixaban Edoxaban Rivaroxaban	Anti-Xa	Absent activity: not clinically relevant Results correlate with drug level (if calibrated for specific DOAC)	PT	Normal: does not exclude clinically relevant levels Prolonged: clinically relevant levels		
Anti-Xa= anti-factor Xa; aPTT= activated partial thromboplastin time; dTT= dilute thrombin time; ECA= ecarin chromogenic assay; ECT= ecarin clotting time; PT= prothrombin time; TT= thrombin time						
Manage Bleeding	All bleeds		Major Bleeds		Minor Bleeds	
	Critical site or life threatening		NOT critical site or life threatening		More serious minor bleeds†	
	Less serious minor bleeds					
	•Provide local therapy/ manual compression •Assess for and manage comorbidities contributing to the bleed*		•Stop DOAC •Provide supportive care •Secure airway and large-bore IV access •Aggressive volume resuscitation (NS or LR) •Correct hypothermia and acidosis •Early involvement of other services (eg. surgery) •RBC transfusions to achieve Hgb ≥7 g/dL (≥8 g/dL if pt has CAD) •Platelet transfusion to achieve counts >50 x 10⁹/L •Cryoprecipitate transfusion to maintain fibrinogen >100 mg/dL •Stop any antiplatelets •Consider surgical/procedural management •Administer reversal agent		•Stop DOAC •Provide supportive care •Secure airway and large-bore IV access •Aggressive volume resuscitation (NS or LR) •Correct hypothermia and acidosis •Early involvement of other services (eg. surgery) •RBC transfusions to achieve Hgb ≥7 g/dL (≥8 g/dL if pt has CAD) •Platelet transfusion to achieve counts >50 x 10⁹/L •Cryoprecipitate transfusion to maintain fibrinogen >100 mg/dL •Stop any antiplatelets •Consider surgical/procedural management •Administer reversal agent if above not effective	•Stop DOAC •Provide supportive care •Stop any antiplatelets •Consider surgical/procedural management
*eg. renal dysfunction, liver disease, thrombocytopenia; †Patient requires hospitalization, transfusion, or procedural intervention						
DOAC Reversal						
Dabigatran			Apixaban, Betrixaban, Edoxaban, Rivaroxaban			
•Administer 5 g idarucizumab IV (two separate 2.5 g/50 mL vials) •If bleeding persists and there is laboratory evidence of persistent dabigatran effect after 12-24 hours, a second dose may be reasonable. •If idarucizumab not available, administer aPCC at 50 units/kg IV (refer to package insert for max units) •Activated charcoal (50 g) can be considered if ingested within 2-4 hours •Hemodialysis could be considered if drug level is high, especially in patients with poor renal function. •Fresh-frozen plasma is not recommended for DOAC reversal			•Admin 4F-PCC 2,000 units IV (fixed dose) OR 25-50 units/kg IV, according to institutional protocol. •If 4F-PCC is not available, consider aPCC 50 units/kg IV (refer to prescribing information for max units) •Consider Activated charcoal (50 g) if ingested <2-4 hrs •Fresh-frozen plasma is not recommended •Andexxa is no longer available in the U.S. due to increased thrombotic risk.			
PCC= prothrombin complex concentrate; aPCC= activated prothrombin complex concentrate						
Restart DOAC	•Most patients benefit from restarting anticoagulation after bleeds, but make sure there is still a valid indication. •eg. CHA₂DS₂-VASC is ≥ 1 (in AF), length of treatment hasn't been reached (for VTE treatment or post-op prophylaxis). •Base plan on the balance between bleeding and thromboembolic risks and discussions with other appropriate practitioners (eg. surgeons), the patient, and caregivers. •Timing of restart: Delay restart if bleeding occurred in a critical site or if patient has a high risk for re-bleeding. Patients with GI bleed should typically wait at least 7-14 days. Patients with intracranial hemorrhage (and no mechanical valve) should wait at least 4 weeks.² In patients with moderate to high risk of recurrent VTE without high risk of recurrent bleeding, ASH suggests resuming anticoagulation within 90 days rather than discontinuation.³ •Make sure dose is correct based on age, renal function, weight, and indication and address any reversible risk factors such as interacting medications or unnecessary antiplatelet therapy.					

• Unless otherwise referenced, document adapted from: 2020 ACC Expert Consensus Decision Pathway on

Management of Bleeding in Patients on Oral Anticoagulants. Am Coll Cardiol 2020;76:594-622.
<https://doi.org/10.1016/j.jacc.2020.04.053>

¹Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz J. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016 Mar;14(3):623-7. doi: 10.1111/jth.13227. Epub 2016 Feb 17.


²Hemphill, et al. 2015 AHA/ASA Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. Stroke. 2015;46:000-000. DOI: 10.1161/STR.0000000000000069

³Witt WM, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. DOI 10.1182/bloodadvances.2018024893

⁴Cuker A, et al. Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. Am J Hematol.2019;94:697–709. doi.org/10.1002/ajh.25475

Disclaimer: This document is for informational purposes only and does not, itself, constitute medical advice. This document is not a replacement for careful medical judgments by qualified medical personnel. There may be information in this document that does not apply to or may be inappropriate for the medical situation at hand.

Intracranial Hemorrhage Guidelines from AHA/ASA 2022⁵



- Unless otherwise referenced, document adapted from: 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. Am Coll Cardiol 2020;76:594-622. <https://doi.org/10.1016/j.jacc.2020.04.053>

¹Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz J. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost. 2016 Mar;14(3):623-7. doi: 10.1111/jth.13227. Epub 2016 Feb 17.

²Hemphill, et al. 2015 AHA/ASA Guidelines for the Management of Spontaneous Intracerebral Hemorrhage. Stroke. 2015;46:000-000. DOI: 10.1161/STR.0000000000000069

³Witt WM, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. DOI 10.1182/bloodadvances.2018024893

⁴Cuker A, et al. Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. Am J Hematol.2019;94:697–709. doi.org/10.1002/ajh.25475

⁵Greenberg et al. 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2022;53:00–00. DOI: 10.1161/STR.0000000000000407

DOAC Reversal Options

	Apixaban	Betrixaban	Dabigatran	Edoxaban	Rivaroxaban
Drug-Specific reversal agent	Andexxa®	Off-label Andexxa®*	Praxbind® (idarucizumab)	Off-label Andexxa®*	Andexxa®
Oral activated charcoal²	Can be considered‡	Can be considered‡	Yes†	Can be considered‡	Can be considered‡
Hemodialysis²	No	No	Can be considered	No	No
Hemoperfusion with activated charcoal²	Unclear	Unclear	Can be considered	Unclear	Unclear
FFP²	No	No	No	No	No
Activated factor VIIa²	Unclear	Unclear	Unclear	Unclear	Unclear
Activated prothrombin complex concentrate (APCC)	Yes ³	Yes ²	Yes ¹	Yes ³	Yes ³
3-factor PCC	Unclear	Unclear	Unclear	Unclear	Unclear
4-factor PCC	Yes ¹	Yes ¹	Yes ²	Yes ¹	Yes ¹

* Suggested off-label dose is an 800 mg bolus given at 30 mg/min followed by a continuous infusion of 8 mg/min for up to 120 min^{1,3}

‡If DOAC taken within past 2 hours.

¹ Cuker A, et al. Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. Am J Hematol.2019;94:697–709. doi.org/10.1002/ajh.25475

² Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation Europace (2015) 17, 1467–1507. doi:10.1093/europace/euv309

³ 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants. Am Coll Cardiol 2020;76:594-622. https://doi.org/10.1016/j.jacc.2020.04.053

Drug Specific DOAC Reversal Agents

	DOAC(s) reversed	Indication(s)	Instructions	Warnings/Precautions
Praxbind® (idarucizumab)¹	dabigatran	- For emergency surgery/urgent procedures - Life-threatening or uncontrolled bleeding	- Administer 5 g intravenously, provided as two separate 2.5 g/50 mL vials. - If administering through an existing intravenous line, flush with 0.9% Sodium Chloride Injection, USP solution prior to infusion. - No other infusion should be administered in parallel via the same intravenous access. - An additional 5 g dose may be administered after 12 to 24 hours if patient has reoccurrence of clinically relevant bleeding and elevated coagulation parameters (eg. aPTT, ECT)²	- Resume anticoagulation as soon as medically appropriate to reduce risk of thromboembolism. Dabigatran can be resumed after 24 hours - Idarucizumab contains 4g of sorbitol. In patients with hereditary fructose intolerance, consider the combined daily metabolic load of sorbitol/fructose from all sources, including idarucizumab and other drugs containing sorbitol to reduce risk of serious adverse reactions.

¹http://us.boehringer-ingelheim.com/content/dam/internet/opu/us_EN/documents/Media_Press_Releases/2015/Praxbind.pdf

² The safety and effectiveness of repeat treatment with idarucizumab have not been established.

Conversion from DOACs to other anticoagulants

	Parenteral Anticoagulants	Warfarin
Dabigatran (Pradaxa®)¹	Discontinue Pradaxa® and start parenteral anticoagulant in 12 hours (CrCl ≥30 mL/min*) or 24 hours (CrCl <30 mL/min*)	- Adjust the starting time of warfarin based on creatinine clearance as follows: - For CrCl ≥50 mL/min*, start warfarin 3 days before discontinuing dabigatran. - For CrCl 30-50 mL/min*, start warfarin 2 days before discontinuing dabigatran. - For CrCl 15-30 mL/min*, start warfarin 1 day before discontinuing dabigatran. - For CrCl <15 mL/min*, no recommendations can be made. - Because dabigatran can increase INR, the INR will better reflect warfarin's effect only after dabigatran has been stopped for at least 2 days
Apixaban (Eliquis®)²	Discontinue Eliquis® and start parenteral anticoagulant at the next scheduled dose of Eliquis®	- Apixaban affects INR, so initial INR measurements during the transition to warfarin may not be useful for determining the appropriate dose of warfarin. - One approach is to discontinue apixaban and begin warfarin with a concomitant parenteral anticoagulant when the next dose of apixaban would have been due, discontinuing the parenteral anticoagulant when INR reaches goal range.
Rivaroxaban (Xarelto®)³	Discontinue Xarelto® and start parenteral anticoagulant at the next scheduled dose of Xarelto®	- No clinical trial data are available to guide converting patients from rivaroxaban to warfarin. - Rivaroxaban affects INR, so INR measurements made during coadministration with warfarin may not be useful for determining the appropriate dose of warfarin. - One approach is to discontinue rivaroxaban and begin both a parenteral anticoagulant and warfarin at the time the next dose of rivaroxaban would have been taken.
Edoxaban (Savaysa®)⁴	Discontinue Savaysa® and start parenteral anticoagulant at the next scheduled dose of Savaysa®	- For patients on 60 mg of edoxaban, reduce dose to 30 mg and begin warfarin concomitantly. - For patients on 30 mg of edoxaban, reduce dose to 15 mg and begin warfarin concomitantly. - During transition, INR should be done at least weekly just prior to daily dose of edoxaban (to minimize influence on INR). - Discontinue edoxaban once a stable INR ≥ 2.0 is achieved.

*CrCl determined using Cockcroft-Gault formula and actual body weight

¹ Pradaxa® [package insert](#)

² Eliquis® [package insert](#)

³ Xarelto® [package insert](#)

⁴ Savaysa® [package insert](#)

DOAC Patient Card Proposed by the European Heart Rhythm Association

Atrial Fibrillation Oral Anticoagulation Card

for non-vitamin-K anticoagulants

Patient name:	DOB:
Patient address:	
Oral anticoagulant, dosing, timing, with or without food:	
Treatment indication:	
Treatment started:	
Name and address of anticoagulant prescriber:	
Telephone number of prescriber or clinic:	



**EUROPEAN
Heart Rhythm
ASSOCIATION**
European Society of Cardiology



**EUROPEAN
SOCIETY OF
CARDIOLOGY®**

More info:

www.NOACforAF.eu
www.noacforaf.eu

Page 1

[illegible][illegible]

Important patient instructions

**Take your drug exactly as prescribed (once or twice daily).
No drug is no protection!**

Never stop your medicine without consulting your physician.

**Never add any other medication without consulting your physician,
not even short-term painkillers that you can get without prescription.**

Alert your dentist, surgeon or other physician before an intervention.

Concomitant medication

Name:	Dose:

Emergency information

Standard tests do not quantitatively reflect level of anticoagulation!

Name & telephone of patient relative to contact if emergency:

Patient blood group (+ physician signature):

Page 4

To print patient cards, go to: <http://www.escardio.org/communities/EHRA/publications/novel-oral-anticoagulants-for-atrial-fibrillation/Documents/English-EHRA-DOAC-card-A7.pdf>

Warfarin Adverse Event Analysis Form

This form can be used to help identify root causes of adverse events and develop action plans to prevent similar events. Using this form ensures that information is collected and analyzed in a systematic way, making it more likely that a root cause is identified and proper prevention strategies put in place.

Patient Information

Pt. Name:	Age:	Warfarin start date: / / Target range: -
Indication: ☐ A-fib/A-flutter ☐ DVT ☐ PE ☐ CM/CHF ☐ Valve Replacement/Repair ☐ MI/LV Thrombus ☐ Hypercoagulable condition ☐ Other:		If indication was DVT or PE, type: ☐ Provoked ☐ Unprovoked ☐ Recurrent
Planned length of treatment: ☐ 1 month ☐ indefinitely ☐ 3 months ☐ other _____ ☐ 6 months ☐ unknown ☐ 1 year		Anticoagulation history: ☐ Prior bleeds ☐ Prior thrombotic event ☐ Hx of non-adherence with warfarin schedule ☐ Hx of non-adherence with INR draws

Adverse Event Information

Date of AE:	INR at time of AE:	Date of INR: / /
Possible reason(s) for out of range INR:		

Type of AE	Location	Severity
☐ Bleed	☐ Intracranial ☐ GI ☐ GU ☐ Other: _____	☐ Minor ☐ Major ☐ Life-threatening ☐ Fatal
☐ Clot	☐ CVA ☐ DVT ☐ Pulmonary Embolism ☐ Peripheral Embolism ☐ Other: _____	

Patient Factors

Concurrent medications	☐ Aspirin (81mg) ☐ Aspirin (325mg) ☐ Clopidogrel ☐ Prasugrel ☐ Ticagrelor ☐ Other anti-platelet: _____ ☐ LMWH ☐ Fondaparinux ☐ Other notable medications: _____
HAS-BLED co-morbidities (if bleeding event)	☐ HTN(1) ☐ Abnormal renal function(1) ☐ Abnormal liver function(1) ☐ Age ≥ 65*(1) ☐ H/o Stroke(1) ☐ H/o bleeding (1) ☐ Labile INRs (TTR < 60%)(1)* ☐ Concomitant antiplatelet or NSAID use(1) ☐ Concomitant alcohol use(1) HAS-BLED score: _____ (A score of 3 or more indicates increased one year bleed risk on anticoagulation sufficient to justify caution or more regular review)

	* If TTR is unavailable, check labile INRs if patient's INRs were generally unstable prior to event.
CHA2DS2-VASc co-morbidities (if embolic stroke event in A-fib patient)	☐ CHF(1) ☐ HTN(1) ☐ Age $\geq$ 75(2) ☐ Age 65-74(1) ☐ H/o Stroke/TIA(2) ☐ H/o vascular disease (MI, PAD, aortic plaque)(1) ☐ Diabetes Mellitus(1) ☐ Female (1) CHA2DS2-VASc score: _____
Clotting risk factors (DVT/PE)	☐ Prior DVT/PE ☐ hypercoagulable state ☐ Cancer ☐ Obesity ☐ CHF ☐ Surgery within past 6 weeks ☐ Lower extremity injury/casting past 6 weeks ☐ Childbirth within past 6 weeks ☐ Oral contraceptive use ☐ Smoking ☐ Age>60 ☐ Prolonged bedrest or periods of sitting ☐ other clotting risk factor(s): _____
Other possible contributing patient factors	☐ Cognitive disorder ☐ Unstable living conditions ☐ H/O non-compliance with dosage ☐ H/O non-compliance with blood draws ☐ Other: _____

Other pertinent information found during chart review

Information from last few anticoagulation related interactions with patient prior to AE
Date of interaction: ____/____/____ Weekly warfarin dose: _____ INR: ____ Date : ____/____/____ Management for INR: ☐ No weekly dose change ☐ Weekly dose change to: _____ ☐ One-time dose increase: _____ ☐ One-time dose decrease: _____ ☐ Dietary Vit. K recommendation: _____ Next scheduled INR: ____/____/____ Other information from interaction: _____
Date of interaction: ____/____/____ Weekly warfarin dose: _____ INR: ____ Date : ____/____/____ Management for INR: ☐ No weekly dose change ☐ Weekly dose change to: _____ ☐ One-time dose increase: _____ ☐ One-time dose decrease: _____ ☐ Dietary Vit. K recommendation: _____

Next scheduled INR: ____/____/____ Other information from interaction: _____ _____ _____
Date of interaction: ____/____/____ Weekly warfarin dose: _____ INR: ____ Date : ____/____/____ Management for INR: ☐ No weekly dose change ☐ Weekly dose change to: _____ ☐ One-time dose increase: _____ ☐ One-time dose decrease: _____ ☐ Dietary Vit. K recommendation: _____ Next scheduled INR: ____/____/____ Other information from interaction: _____

Root Cause Analysis

When doing the root cause analysis, focus on finding process/system/environmental vulnerabilities that, if “fixed” would have prevented the event. If a human error is involved, try to identify any system, process, or environmental factors that contributed to the error.		
Start by identifying the High Level cause for the event: ☐ High INR ☐ Low INR ☐ Co-morbid conditions ☐ unknown ☐ Other: _____		
Then, use the categories below to brainstorm the most likely factor(s) that contributed to the event.		
Category	Description/Examples	Contributing factors
Patient-Specific factors	Pre-existing or co-morbid medical conditions, concurrent medications, physical limitations, language and communication barriers, cultural issues, or social support	_____ _____ _____
Policies/Procedures/Protocol issues	Are they complete, updated, and accurate? Did they cover this situation adequately? Were they used properly in this situation?	_____ _____ _____
Human resource issues	Is staffing adequate? Is staff properly trained? Does staff have proper supervision?	_____ _____ _____
Communication issues	Was there a communication issue between staff, the patient, or providers that contributed?	_____ _____ _____

Information management issue	Was necessary information available, accurate, and complete?				
Information Technology/ Equipment	Was there a technical or equipment issue that contributed?				
Other contributing factors					
From the list of contributing factors, pick the most likely contributing factor(s) that <u>can be controlled and addressed</u> and try to drill down to the root cause. Perform a “5 Whys” to help drill down to the root cause. A root cause is a factor that, if removed, would have prevented the event from happening.					
<table border="1"> <tr> <td> Drill down to root-cause • If possible, keep asking “why” until you feel you have identified the root cause for the AE. • Use cause and effect (fishbone) diagrams, if necessary. Example: 1. Why was her INR high?..She took more than prescribed. 2. Why did she take more than prescribed?....She didn't get the message to decrease dose. 3. Why didn't she get the message to decrease dose?....ACS was leaving a message on the wrong number. 4. Why was the ACS leaving a message at the wrong number?....New staff member was looking at the wrong number in the record system. 5. Why was the staff member looking at the wrong number?....She wasn't trained properly on the new system (root cause). </td> <td colspan="2"> 1. Why _____? - Answer: _____ 2. Why _____? - Answer: _____ 3. Why _____? - Answer: _____ 4. Why _____? - Answer: _____ 5. Why _____? - Answer: _____ Root cause(s): _____ _____ </td> </tr> </table>			Drill down to root-cause • If possible, keep asking “why” until you feel you have identified the root cause for the AE. • Use cause and effect (fishbone) diagrams, if necessary. Example: 1. Why was her INR high?..She took more than prescribed. 2. Why did she take more than prescribed?....She didn't get the message to decrease dose. 3. Why didn't she get the message to decrease dose?....ACS was leaving a message on the wrong number. 4. Why was the ACS leaving a message at the wrong number?....New staff member was looking at the wrong number in the record system. 5. Why was the staff member looking at the wrong number?....She wasn't trained properly on the new system (root cause).	1. Why _____? - Answer: _____ 2. Why _____? - Answer: _____ 3. Why _____? - Answer: _____ 4. Why _____? - Answer: _____ 5. Why _____? - Answer: _____ Root cause(s): _____ _____	
Drill down to root-cause • If possible, keep asking “why” until you feel you have identified the root cause for the AE. • Use cause and effect (fishbone) diagrams, if necessary. Example: 1. Why was her INR high?..She took more than prescribed. 2. Why did she take more than prescribed?....She didn't get the message to decrease dose. 3. Why didn't she get the message to decrease dose?....ACS was leaving a message on the wrong number. 4. Why was the ACS leaving a message at the wrong number?....New staff member was looking at the wrong number in the record system. 5. Why was the staff member looking at the wrong number?....She wasn't trained properly on the new system (root cause).	1. Why _____? - Answer: _____ 2. Why _____? - Answer: _____ 3. Why _____? - Answer: _____ 4. Why _____? - Answer: _____ 5. Why _____? - Answer: _____ Root cause(s): _____ _____				
<table border="1"> <tr> <td> Root cause category (for tracking purposes, if needed) </td> <td> ☐ Patient-Specific factors ☐ Human Resource ☐ Information Management ☐ Other _____ </td> <td> ☐ Policies/Procedures/Protocols ☐ Communication ☐ Information technology/equipment </td> </tr> </table>			Root cause category (for tracking purposes, if needed)	☐ Patient-Specific factors ☐ Human Resource ☐ Information Management ☐ Other _____	☐ Policies/Procedures/Protocols ☐ Communication ☐ Information technology/equipment
Root cause category (for tracking purposes, if needed)	☐ Patient-Specific factors ☐ Human Resource ☐ Information Management ☐ Other _____	☐ Policies/Procedures/Protocols ☐ Communication ☐ Information technology/equipment			


Action Plan

Is this an isolated incident or is this part of a larger trend?	☐ Isolated incident ☐ Part of a larger trend
What action(s) will be taken to address this root cause to prevent it from happening again?	☐ No action clearly needed at this time. Will continue to monitor for trends indicating a need for system/process change. ☐ Process/Workflow improvement: _____ _____ ☐ Structure/Staffing change: _____ _____ ☐ Protocol change: _____ _____ ☐ Communication change: _____ _____ ☐ Staff education: _____ _____ ☐ Other change: _____ _____
Follow-up on plan	Date: ____/____/____ Status: _____ _____ _____ _____ _____ Date: ____/____/____ Status: _____ _____ _____ _____ _____ Date: ____/____/____ Status: _____ _____ _____ _____ _____

Timeline and INR Graph (if needed)

Date				
INR				
What happened?				


INR Graph



Anticoagulation in Special Populations

Atrial Fibrillation in pregnancy and breastfeeding¹

- There is general consensus that in order to minimize the risk of warfarin embryopathy, it is reasonable to avoid warfarin between weeks 6 and 12 of gestation because of the high risk of fetal defects, especially if the dose of warfarin is higher than 5 mg per day.
- For women receiving oral anticoagulant (OAC) for prevention of stroke/TE in AF who become pregnant, CHEST guidelines suggest discontinuation of OAC with a VKA between weeks 6 and 12 and replacement by LMWH twice daily (with dose adjustment according to weight and target anti-Xa level 4-6 h post-dose 0.8-1.2 U/mL), especially in patients with a warfarin dose required of > 5 mg/day (or phenprocoumon > 3 mg/day or acenocoumarol > 2 mg/day) (Ungraded consensus-based statement).
- If patient was switched back to OAC after 12 weeks, OAC should then be replaced by adjusted-dose LMWH (target anti-Xa level 4-6 h post-dose 0.8-1.2 U/mL) in the 36th week of gestation (Ungraded consensus-based statement).



- For women on treatment with long-term vitamin K antagonists who are attempting pregnancy and are candidates for LMWH substitution, CHEST guidelines suggest performing frequent pregnancy tests and

use LMWH instead of VKA when pregnancy is achieved rather than switching to LMWH while attempting pregnancy (Ungraded consensus-based statement).

- For pregnant women, CHEST guidelines suggest avoiding the use of DOACs (Ungraded consensus-based statement).
- For lactating women using warfarin, acenocoumarol, or UFH who wish to breast-feed, CHEST guidelines suggest continuing the use of warfarin, acenocoumarol, LMWH, or UFH (Ungraded consensus-based statement)
- For breast-feeding women, CHEST guidelines suggest alternative anticoagulants rather than DOACs (Ungraded consensus-based statement).

¹Lipp G, et al. Antithrombotic Therapy for Atrial Fibrillation CHEST Guideline and Expert Panel Report. CHEST 2018; 154(5):1121-1201

VTE in pregnancy and breastfeeding

Question	Recommendation ¹
Treatment of acute VTE and superficial vein thrombosis in pregnancy	
Do you anticoagulate in acute VTE?	Antithrombotic therapy is recommended .
Which anticoagulant should be used?	Low-molecular-weight heparin (LMWH) is recommended over unfractionated heparin (UFH) or any oral anticoagulant.
Do you use once-per-day or twice-per-day LMWH dosing in acute VTE?	Either dosing regimen is acceptable. (note: These guidelines do not specify if pre-pregnancy weight or weight at time of diagnosis of VTE should be used for dosing)
Do you anticoagulate in acute superficial vein thrombosis?	Anticoagulation with LMWH is suggested . (note: The guideline committee did not reach agreement on LMWH dosing, but there was consensus that patients should be treated for the remainder of the pregnancy and 6 weeks post-partum.)
Do patients receiving therapeutic LMWH need routine monitoring of anti-FXa levels to guide dosing?	Routine monitoring of anti-FXa levels to guide dosing is not suggested .
Do patients with low-risk acute VTE require a hospital admission?	Initial outpatient therapy over hospital admission is suggested Vital sign abnormalities, severe pain requiring analgesia, extensive VTE, advanced gestational age, maternal comorbidities that limit tolerance of recurrent VTE or are associated with increased risk of bleeding, contraindications to LMWH, and lack of adequate support at home are all indicators for initial hospitalization.
Should delivery be scheduled or spontaneous?	- If receiving therapeutic-dose LMWH for management of VTE, scheduled delivery with prior discontinuation of anticoagulant therapy is suggested. - If receiving prophylactic-dose LMWH, spontaneous delivery is suggested.
What anticoagulant should be used during breastfeeding?	UFH, LMWH, warfarin, fondaparinux, or danaparoid are recommended. - The agents with greatest experience in this patient population and the best evidence for safety are warfarin, acenocoumarol, and LMWH. - Direct Oral Anticoagulants (DOACs) are not recommended.

Question	Recommendation ¹
VTE Prevention in pregnancy	
Should anticoagulant prophylaxis be used in women undergoing assisted reproduction?	Prophylactic antithrombotic therapy to prevent VTE is not suggested (except in severe ovarian hyperstimulation syndrome). Prophylaxis is suggested in patients that develop severe ovarian hyperstimulation syndrome.
Should <u>antepartum</u> anticoagulant prophylaxis be used for pregnant patients with prior VTE?	- For women who have a history of VTE that was unprovoked or was associated with a hormonal risk factor, antepartum anticoagulant prophylaxis is recommended. - For women who have a history of prior VTE associated with a non-hormonal temporary provoking risk factor and no other risk factors, antepartum anticoagulant prophylaxis is not suggested.
Should <u>postpartum</u> anticoagulant prophylaxis be used for women with prior VTE?	Postpartum anticoagulant prophylaxis is recommended.
Should <u>antepartum</u> anticoagulant prophylaxis be used for pregnant women with thrombophilia to prevent a first venous thromboembolic event?	- For women who are heterozygous for the factor V Leiden or prothrombin mutation and in those who have protein C or protein S deficiency, regardless of family history of VTE, antepartum antithrombotic prophylaxis is not suggested. - For women who have no family history of VTE but have antithrombin deficiency or are homozygous for the prothrombin gene mutation, antepartum antithrombotic prophylaxis is not suggested. - For women with antithrombin deficiency who have a family history of VTE and in those who are homozygous for the factor V Leiden mutation or who have combined thrombophilias, regardless of family history of VTE, antepartum antithrombotic prophylaxis is suggested.
Should <u>postpartum</u> anticoagulant prophylaxis be used for pregnant women with thrombophilia to prevent a first venous thromboembolic event?	- For women without a family history of VTE who are heterozygous for the factor V Leiden mutation or prothrombin mutation or who have antithrombin, protein C, or protein S deficiency, antithrombotic prophylaxis is not suggested. - For women with a family history of VTE who are heterozygous for the factor V Leiden mutation or prothrombin mutation,

Question	Recommendation ¹
	postpartum antithrombotic prophylaxis is not suggested. - For women with a family history of VTE who have antithrombin deficiency, postpartum antithrombotic prophylaxis is recommended. - For women with a family history of VTE who have protein C or protein S deficiency, postpartum antithrombotic prophylaxis is suggested. - For women with combined thrombophilias or who are homozygous for the factor V Leiden mutation or prothrombin gene mutation, regardless of family history, postpartum antithrombotic prophylaxis is suggested.
Should anticoagulant prophylaxis be used for pregnant women with clinical risk factors for VTE (Other than known thrombophilia or history of VTE)?	For women with no or 1 clinical risk factor (excluding a known thrombophilia or history of VTE), antepartum or postpartum prophylaxis is not suggested. Examples of clinical risk factors include: increased body mass index, immobilization, medical comorbidities, and placental-mediated pregnancy complications
Should intermediate-dose LMWH prophylaxis or standard-dose LMWH prophylaxis be used for preventing first or recurrent VTE in pregnant women?	- Standard-dose LMWH prophylaxis during the antepartum period is suggested. - Either standard- or intermediate-dose LMWH prophylaxis during the postpartum period is suggested. [note: For the purposes of this guideline, the committee defined intermediate dose as any dose greater than the standard prophylactic dose (40 mg once per day) but less than the therapeutic dose(1.5mg/kg/day or 1mg/kg/bid).]

More information about the American Society of Hematology guidelines for VTE in pregnancy, including the full guidelines, a mobile app, and teaching slides are available at:

<https://www.hematology.org/education/clinicians/guidelines-and-quality-care/clinical-practice-guidelines/venous-thromboembolism-guidelines/pregnancy>

¹Bates S, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Advances 2018 2:3317-3359; doi: <https://doi.org/10.1182/bloodadvances.2018024802>

Unique Venous Thrombosis Situations

Location of Thrombosis	Anticoagulation recommendations
Splanchnic vein¹ (portal, mesenteric, or splenic vein thrombosis, and Budd-Chiari syndrome)	<pre> graph TD A[Acute symptomatic] --> B{Shock, high lactate levels or signs of peritonitis, perforation, intestinal infarct, or acute major GIB?} B -- Yes --> C[Immediate surgical evaluation/treatment before introducing anticoagulation] B -- No --> D[Start early anticoagulation*] D --> E[Non-cirrhotic and no other contraindications to DOACs] D --> F[Cancer-associated] D --> G[Cirrhotic†] D --> H[Non-cirrhotic but contraindications to DOACs] D --> I[CrCl<30 mL/min] F --> J{Luminal GI CA, active GI mucosal abnormalities, GU CA at high-risk of bleeding, or drug-drug interactions with DOAC?} J -- Yes --> K[Therapeutic dose LMWH*] J -- No --> L[Full therapeutic dose DOAC*] G -- Yes --> K G -- No --> M[VKA INR range 2-3]*] H --> M I --> N[Initial treatment with UFH, apix, riva, or half therapeutic dose LMWH**] </pre> * If high risk of major bleeding, individualized dose reduction or delayed treatment is suggested. Withholding anticoagulation in patients with poor short-term prognosis is also suggested. †LMWH suggested for initial treatment and then switch to VKAs or DOACs if not contraindicated by severity of liver dysfunction. **UFH suggested if creatinine clearance <15 mL/min. <u>Length of treatment for acute symptomatic thrombosis:</u> At least 3 to 6 months of anticoagulation, irrespective of thrombosis extension and underlying risk factors. Longer treatment or indefinite anticoagulant treatment in patients with thrombosis progression or recurrence after treatment discontinuation, unprovoked splanchnic vein thrombosis, or persistent risk factors. <u>Chronic thrombosis:</u> Careful evaluation of the use of anticoagulation on a case-by-case basis with consideration of a watchful approach to minimize bleeding <u>Incidentally detected thrombosis:</u> Use same treatment as for symptomatic acute thrombosis <u>Budd-Chiari syndrome:</u> Indefinite anticoagulation with LMWH, DOACs (if not contraindicated), or VKA with target INR range 2-3 (in patients with contraindications for DOACs)

Location of Thrombosis	Anticoagulation recommendations
Cerebral vein/cerebral venous sinus²	Anticoagulation therapy is recommended for at least the treatment phase (first 3 months). No specific anticoagulant is recommended, although the guidelines mention that most evidence supporting anticoagulation comes from studies using LMWH and that there have been no randomized trials evaluating the use of DOACs in these patients as of the writing of the guidelines.
Upper extremity³	In acute upper-extremity DVT involving the axillary or more proximal veins, anticoagulation is recommended. - Length of treatment: - Associated with central venous catheter with or without cancer - Catheter has been removed→3 months of treatment - Catheter not removed→Continue treatment as long as catheter remains - Not associated with central venous catheter or cancer→3 months of treatment
Retinal⁴	Routine use of antithrombotic drugs for retinal vein occlusion is not recommended. - Antithrombotic treatment may be considered in select patients with recent onset and no local risk factors for thrombosis (e.g. glaucoma) or in patients with underlying major prothrombotic risk factors such as antiphospholipid antibodies syndrome. - If it is determined to treat, therapeutic doses of LMWH may be considered for the acute phase (1-3 months) - Pts with relevant arterial disease should be treated with aspirin for an indefinite period instead of LMWH.
Acute isolated distal DVT of leg²	- Without severe symptoms or risk factors for extension* - Serial imaging of the deep veins for 2 weeks - no anticoagulation if thrombus does not extend - If thrombus extends, anticoagulation suggested (if remains in distal veins) but recommended (if extends to proximal veins) - With severe symptoms or risk factors for extension* - Anticoagulation suggested *examples of risk factors for extension: D-dimer is positive (particularly when markedly so without an alternative reason); thrombosis is extensive (eg, >5 cm in length, involves multiple veins, >7 mm in maximum diameter); thrombosis is close to the proximal veins; there is no reversible provoking factor for DVT; active cancer; history of VTE; and inpatient status
Sub-segmental PE without proximal DVT²	- Low Risk for VTE Recurrence and Asymptomatic→no anticoagulation can be considered in a shared decision-making model - High Risk for VTE Recurrence* and/or Symptomatic→anticoagulation suggested *ex. hospitalized/reduced mobility, active CA, pregnancy

Location of Thrombosis	Anticoagulation recommendations
Asymptomatic Incidentally found PE²	Same initiation and treatment phase anticoagulation as for comparable patients with symptomatic PE
Superficial venous thrombosis (SVT) of lower limb²	45 days of anticoagulation suggested (if increased risk of clot progression to DVT or PE*) • Fondaparinux 2.5mg daily suggested ○ If unable/unwilling to take fondaparinux→rivaroxaban 10mg daily suggested *ex. extensive SVT, involvement above the knee, severe symptoms, involvement of greater saphenous vein, hx of VTE, active CA, recent surgery

¹ Anticoagulant therapy for splanchnic vein thrombosis: ISTH SSC Subcommittee Control of Anticoagulation. J Thromb Haemost. 2020;18:1562–1568

² Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. CHEST 2021; 160(6):2247-2259

³ Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST 2012; 141(2)(Suppl):e419S–e494S.

⁴ Guidance for the management of venous thrombosis in unusual sites. J Thromb Thrombolysis (2016) 41:129–143

Anticoagulant-Antiplatelet Combination Therapy

Many patients with an indication for anticoagulation may also have an indication for single or dual antiplatelet therapy. The table below covers some possible indications for combination therapy and the research and guidelines for these situations.

Indication for combination therapy	Information
Primary CVD prevention	The use of aspirin for primary prevention of atherosclerotic cardiovascular disease (ASCVD) should no longer be routine based on the 2019 AHA/ACC guidelines for primary prevention of cardiovascular disease.¹ According to the new guidelines, <u>aspirin should now only be considered in patients with the highest ASCVD risk and no increased bleeding risk</u> (eg. concomitant use of anticoagulants) due to lack of a clear net benefit.
Secondary prevention of CV events in stable CAD or PAD <u>without another indication for anticoagulation</u>	The COMPASS trial showed that patients taking rivaroxaban (2.5mg BID) + aspirin had a reduction in cardiovascular events but higher major bleeding.² • The increase in bleeding events were mostly GI bleeding. There was no increase in intracranial or fatal bleeding. • The greatest benefit of this combination therapy is expected in the highest risk patients (eg. polyvascular disease, HF, diabetes, and CKD). The FDA has approved the 2.5mg BID dose of rivaroxaban for this indication. More information on this topic can be found in this AC Forum Centers of Excellence Rapid Resource: Peripheral Artery Disease and Dual Inhibition Therapy.
Secondary CV event prevention in AF or VTE patients <u>with recent ACS/PCI</u>	Triple therapy (anticoagulant + dual antiplatelet) may only be needed for the highest risk patients following recent ACS or PCI. • Several studies now suggest that dual therapy (anticoagulant + clopidogrel) may best balance ischemic and bleeding event risk for most patients. ○ Warfarin + clopidogrel (WOEST trial) ○ Rivaroxaban + clopidogrel (PIONEER AF-PCI) ○ Dabigatran + clopidogrel (RE-DUAL PCI) ○ Apixaban + clopidogrel (AUGUSTUS) In patients requiring combination therapy, the 2020 AHA/ACC guidelines recommend clopidogrel (over other antiplatelets) in combination with a DOAC (over VKA)³ These guidelines recommend gastroprotection with a proton-pump inhibitor to reduce GI bleed risk while on combination therapy.

Indication for combination therapy	Information
Secondary CV event prevention in AF or VTE patients with stable CAD and <u>no ACS/PCI within 12 months</u>	In AF patients with stable CAD, there is little evidence that adding antiplatelet therapy to patients already taking anticoagulants reduces stroke/systemic embolism, death, or MI. However, the risk of major bleeding and ICH is substantially increased.^{4,5} CHEST and European Society of Cardiology guidelines for AF recommend oral anticoagulation monotherapy in AF patients with stable CAD and no PCI/ACS in the previous 12 months^{4,6} ACC/AHA guidelines recommend oral anticoagulation monotherapy in most AF or VTE patients with PCI >12 months ago. If perceived thrombotic risk is high and bleeding risk is low, continued single antiplatelet therapy (ASA 81 mg daily or clopidogrel 75 mg daily) in combination with oral anticoagulation is reasonable.³
Peripheral Artery Disease (PAD) in patients with an existing indication for oral anticoagulation	In PAD patients with an indication for full-dose oral anticoagulation, the addition of antiplatelet therapy should generally be avoided, unless endovascular intervention/stenting was recently performed,^{3,7} or if patient has high thrombotic risk and bleeding risk has been considered.⁷ If endovascular intervention/stenting was performed, the duration of single-antiplatelet therapy should be as limited as possible (1-3 months)^{3,7}
Artificial valves	<u>Mechanical valves</u>: Warfarin alone is the recommended antithrombotic therapy. Adding aspirin (75-100mg) daily may be considered if there is another clear indication for anti-platelet therapy and the patient otherwise has low bleed risk.⁸ <u>On-X (mechanical)</u>: Aspirin (75-100mg) daily is recommended in combination with warfarin.⁸ <u>Surgical bioprosthetic</u>: Aspirin is not recommended in combination with oral anticoagulation. Aspirin (75-100mg) daily is reasonable if patient has no other indication for anticoagulation (ex. AF).⁸ <u>TAVR (bioprosthetic)</u>: Aspirin is not recommended in combination with oral anticoagulation. Aspirin (75-100mg) daily is reasonable if patient has no other indication for anticoagulation (ex. AF).⁸

¹ 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease. Journal of the American College of Cardiology (2019). <https://doi.org/10.1016/j.jacc.2019.03.010>

²Eikelboom J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017; 377:1319-1330. DOI: 10.1056/NEJMoa1709118

³2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients with Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic

Cardiovascular Diseases. J Am Coll Cardiol. 2021 Feb 9;77(5):629-658. doi: 10.1016/j.jacc.2020.09.011. Epub 2020 Nov 26. PMID: 33250267.

⁴Lipp G, et al. Antithrombotic Therapy for Atrial Fibrillation CHEST Guideline and Expert Panel Report. CHEST 2018; 154(5):1121-1201

⁵Yasuda S, et al. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. N Engl J Med 2019; 381:1103-1113. DOI: 10.1056/NEJMoa1904143


⁶2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 Oct 7; 37(38):2893-2962.

⁷ Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy. European Heart Journal (2021) 42, 4013–4024. doi:10.1093/eurheartj/ehab390

⁸ 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease. Circulation. 2021;143:e72–e227. DOI: 10.1161/CIR.0000000000000923

VTE Prevention in Ambulatory Cancer Patients

Patients with active cancer have an increased risk of VTE. Two recent trials (AVERT¹ and CASSINI²) have shown that DOACs can reduce VTE risk in ambulatory cancer patients initiating chemotherapy. The following flowchart is based on a guidance statement from the International Society on Thrombosis and Haemostasis.³



*See the following page for the Khorana score calculation. Consult with a pharmacist or hematologist to evaluate for potential DOAC drug-drug interactions.

** Apixaban or rivaroxaban recommended since they were used in the AVERT and CASSINI trials. Treatment up to 6 months after initiation of chemotherapy is suggested. Regular monitoring of platelet counts and bleeding risk complications is recommended.³

*** In high-risk ambulatory cancer patients where primary thromboprophylaxis is planned but with concerns for safety of DOACs (such as in patients with concern of drug interaction or high risk of gastrointestinal bleeding), prophylactic doses of LWMH is suggested.³

To evaluate VTE risk in cancer patients receiving outpatient chemotherapy, the Khorana Score can be utilized.⁴

Khorana Score

Patient Characteristic	Risk Score
Cancer location: stomach or pancreas (very high risk)	2
Cancer location: lung, lymphoma, gynecologic, bladder, testicular (high risk)	1
Pre-chemotherapy platelet count $\geq 350 \times 10^9/L$	1
Hemoglobin < 10 g per deciliter or use of red blood cell growth factors	1
Pre-chemotherapy leukocyte count $> 11 \times 10^9/L$	1
Body Mass Index $\geq 35 \text{ kg/m}^2$	1

VTE Risk	Total Score
Low	0
Intermediate	1-2
High	≥ 3

¹Carrier M, et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer (AVERT trial). N Engl J Med 2019; 380:711-719. DOI: 10.1056/NEJMoa1814468

²Khorana A, et al. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med 2019; 380:720-728. DOI: 10.1056/NEJMoa1814630

³Wang T, et al. The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH. J Thromb Haemost. 2019;17:1772-1778.

⁴Khorana A, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood (2008) 111 (10): 4902-4907. doi.org/10.1182/blood-2007-10-116327

VTE Treatment/Prophylaxis in COVID-19

COVID-19 patients may be at increased risk of both venous and arterial thrombosis, requiring the need for screening and possible prophylaxis or treatment with anticoagulants.^{1, 2} Several organizations have put together anticoagulation resources to help providers take care of COVID-19 patients.

Anticoagulation Forum:

- [Interim guidance on thromboembolism and anticoagulant therapy during the COVID-19 pandemic](#)
- [The Centers of Excellence Resource Center](#)

American Society of Hematology (ASH):

- [VTE anticoagulation FAQs](#)
- [COVID-19 resource page](#)

International Society on Thrombosis and Haemostasis (ISTH):

- [COVID-19 resources page](#)
- [2023 ISTH guidelines for antithrombotic treatment in COVID-19](#)

North American Thrombosis Forum (NATF):

- [COVID-19 resources page](#)

National Institute of Health (NIH):

- [Antithrombotic Therapy in COVID-19 Patients](#)

Special note: Since Paxlovid™ contains ritonavir, a combined P-gp inhibitor and strong CYP3A4 inhibitor which can increase DOAC drug levels and increase bleed risk, it is important to recognize this potential drug interaction and consider options for reducing the DOAC dose or switching to an alternative anticoagulant during Paxlovid™ treatment, using an alternative COVID-19 treatment, or holding anticoagulation in cases of low patient thromboembolic risk. [See Drug-Drug Interactions with DOACs](#) for more information.

1. Bikdeli, et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up. J Am Coll Cardiol. 2020 Jun, 75 (23) 2950-2973. DOI: 10.1016/j.jacc.2020.04.031

2. Barnes, G.D., Burnett, A., Allen, A. et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. J Thromb Thrombolysis (2020). <https://doi.org/10.1007/s11239-020-02138-z>

Perioperative antiplatelet management

Surgery/procedure type	ASA	P2Y12 inhibitors
Minor dental, dermatological, or ophthalmologic procedures	continue	continue (if also on ASA, stop the P2Y12 inhibitor)
Other non-cardiac	continue*	stop**
CABG	continue	stop**
Surgery/procedure within <u>6-12 weeks</u> of coronary stent placement in patients on dual antiplatelet therapy	continue both or stop one 7-10 days before procedure	continue both or stop one 7-10 days before procedure
Surgery/procedure within <u>3-12 months</u> of coronary stent placement in patients on dual antiplatelet therapy	continue	stop**

*May stop ≤ 7 days before high bleeding risk surgeries (eg. intracranial, spinal)

**Timing of interruption dependent on P2Y12 inhibitor

- 3-5 days before if ticagrelor
- 5 days before if clopidogrel
- 7 days before if prasugrel

Restart antiplatelet ≤ 24 hrs after procedure

Anticoagulation in Cirrhosis¹

Indication and severity of cirrhosis		Need for anticoagulation	Choice of anticoagulant
Stroke prevention in AF	Child–Pugh A or B	- Anticoagulation is recommended in patients with CHA₂DS₂VASc score of ≥2 (males) or ≥3 (females) unless otherwise contraindicated. - Anticoagulation is suggested in patients with CHA₂DS₂VASc score of 1 (males) or 2 (females) unless otherwise contraindicated.	- A DOAC at standard doses is suggested in preference to warfarin based on available evidence suggesting greater efficacy and safety. - There is inadequate evidence to recommend for or against a specific DOAC¹, however edoxaban and rivaroxaban are not recommended in Child-Pugh B per package inserts.
	Child–Pugh C	There is inadequate evidence with respect to the benefit and risk of anticoagulation.	
VTE treatment	Child–Pugh A or B	Anticoagulation should be offered barring a contraindication such as active bleeding. Anticoagulation is suggested in patients with moderate thrombocytopenia secondary to advanced liver disease. A case-by-case decision should be made when the platelet count is $<50 \times 10^9/L$, based on site and extent of thrombosis and patient risk factors.	DOACs, LMWH (alone) or warfarin (after LMWH bridging) are suggested based on patient preference. - Edoxaban and rivaroxaban are not recommended in Child-Pugh B per package inserts.
	Child–Pugh C		LMWH (alone) or warfarin (after bridging with LMWH in patients with a normal baseline INR) is suggested.
Portal vein thrombosis	Child–Pugh A or B	Anticoagulation recommended for all patients with symptomatic PVT for a minimum of 6 months. Anticoagulation is suggested for all patients with asymptomatic, but progressing PVT for a minimum of 6 months, unless there are clear contraindications to anticoagulation. Extended anticoagulation is recommended for all patients who are candidates for liver transplantation unless patients are actively bleeding.	DOACs, LMWH (alone) or warfarin (after LMWH bridging) are suggested based on patient preference. - Edoxaban and rivaroxaban are not recommended in Child-Pugh B per package inserts.
	Child–Pugh C	Anticoagulation may be considered in patients with asymptomatic PVT who are not candidates for liver transplantation on a case-by-case basis (assess bleeding risk every 6-months and discontinue if active bleeding or significant increased bleed risk).	LMWH (alone) or warfarin (after bridging with LMWH in patients with a normal baseline INR) is suggested.

¹Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, Volume 22, Issue 9, 2653 – 2669

Link to AC Forum webinar (10/8/2024): <https://acforum.org/web/education-webinar.php?id=8660>

Anticoagulation Links

Organization/Document	Description	Link
Anticoagulation Forum	The largest peer organization of anticoagulant service providers in North America. Members include international anticoagulation experts that provide education and guidance for applying the latest research into practice.	http://acforum.org
Anticoagulation Centers of Excellence	Part of the Anticoagulation Forum, this program offers providers guidelines, tools, and other information in order to achieve the highest possible level of care and improve outcomes.	http://excellence.acforum.org/
AC Forum Clinical Guidance	Guidance provided by panels of clinical experts across several topics, including management of VTE and reversal of Direct Oral Anticoagulants.	https://acforum.org/web/education-guidance.php
AC Forum Core Elements of Anticoagulation Stewardship Programs	Key steps in developing a coordinated, system-level program that health systems can implement to improve anticoagulation-related outcomes and reduce adverse events.	https://acforum.org/web/education-stewardship.php
American College of Chest Physicians-Antithrombotic Guidelines	A leading source for evidence-based antithrombotic guidelines.	http://www.chestnet.org/Guidelines-and-Resources/Guidelines-and-Consensus-Statements/Antithrombotic-Guidelines-9th-Ed
American College of Physicians Atrial Fibrillation patient resources	Excellent resources for providers to give to patients with AF. Hard copies of the pamphlet and DVD copies of the videos can be ordered for free from this link	Afib-What you and your family should know (pamphlet) Afib-What you and your family should know (video) Stroke and Stroke Risk (video) Afib Medications (video) Afib Self Management (video)
Society of Vascular Medicine	Society of Vascular Medicine (http://www.vascularmed.org/) is a professional organization that was founded in 1989 to foster a broad mission. The goals of the Society are to improve the integration of vascular biological advances into medical practice, and to maintain high standards of clinical vascular medicine.	- Online shared decision making tool for anticoagulant choice in AF: http://www.mybloodclots.org/ - Online toolkit to help providers develop an outpatient DVT diagnosis and treatment pathway: www.mydeepveinthrombosis.com/

American Society of Hematology (ASH)-Clinical Practice Guidelines	Since 2014, ASH has developed clinical practice guidelines for venous thromboembolism. Over 200 evidence-based recommendations are available across various topics.	https://www.hematology.org/vte/
Clot Care	This organization provides information and expert insight on the optimal use of antithrombotic and anticoagulant therapy. Patient and provider resources are available.	www.clotcare.org
Clot Connect	A project from the University of North Carolina at Chapel Hill's Hemophilia and Thrombosis Center which connects providers and patients to clinically relevant education resources on deep vein thrombosis, pulmonary embolism, thrombophilia and anticoagulation.	http://www.clotconnect.org/
National Blood Clot Alliance	An organization that provides information and resources to providers and patients on the prevention, early diagnosis, and treatment of life-threatening blood clots.	http://www.stoptheclot.org/
World Thrombosis Day	A website sponsored by International Society on Thrombosis and Haemostasis to increase awareness of VTE.	http://www.worldthrombosisday.org

Acknowledgements

On behalf of the Michigan Anticoagulation Quality Improvement Initiative (MAQI²) consortium, we would like to thank the following individuals who have been involved with the development and review of this toolkit.

Beaumont Oakland University School of Medicine Mona Ali, PharmD, BCPS Steve Almany, MD Nannette Gearhart, RN, MSN	University of Michigan-Ann Arbor, MI James Froehlich, MD, MPH Geoffrey Barnes, MD, MSc Eva Kline-Rogers, MS, RN Brian Haymart, MS, RN Tina Alexandris-Souphis, RN, BSN Debbie DeCamillo, RN, BSN Nghi Ha, Pharm.D. Elizabeth Renner, Pharm.D. Brian Kurtz, Pharm.D.
Cardiology and Vascular Associates-Commerce, MI Jay Kozlowski, MD	Corewell West-Grand Rapids, MI Mary Jo DeYoung, RN Musa Dahu, MD Michael McNamara, MD
Henry Ford Hospital-Detroit, MI Scott Kaatz, DO, MSc Gregory Krol, MD Vinay Shah, MD Syed Ahsan, MD Noelle Ryan, Pharm.D. Stacy Ellsworth, RN, MS	Henry Ford St. John Hospital Christopher Giuliano, PharmD, MPH Stephanie Edwin, PharmD Paul Dobry, PharmD
Trinity Health-Ann Arbor Cherise Callahan, PharmD	Representatives of the Michigan Academy of Family Physicians Robert Jackson, MD Ekram Smith, MD

Support for MAQI² and toolkit development provided by:

